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 i 
ABSTRACT 
Viral protein U (Vpu) is a type-III integral membrane protein encoded by the Human 
Immunodeficiency Virus-1 (HIV- 1). It is expressed in infected host cells and plays vital 
roles in down-regulation of CD4 receptors in T cells and also in the budding of virions. But, 
there remain key structure/function questions regarding the mechanisms by which the Vpu 
protein contributes to HIV-1 pathogenesis and thus, it makes for an attractive target to 
study the structural attributes of this protein by elucidating a structural model with X-ray 
crystallography. This study describes a multi-pronged approach of heterologous over-
expression of Vpu. The strategies of purification and biophysical/ biochemical 
characterization of the different versions of the protein to evaluate their potential for 
crystallization are also detailed. Furthermore, various strategies employed for the 
crystallization of Vpu by both in surfo and in cubo techniques, and the challenges faced 
towards the structural studies of this membrane protein by characterization with solution 
Nuclear magnetic resonance (NMR) spectroscopy are also described. 
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I. The HIV-1 Viral Protein U 
Introduction 
The Human immunodeficiency virus (HIV) is a member of the genus Lentivirus, 
which is a subgroup of the family Retroviridae, that causes a condition of progressive 
failure of the immune system called the Acquired Immunodeficiency Syndrome (AIDS). 
Out of the two types of this virus (HIV-1 and HIV-2), HIV-1 has been the cause of the 
majority of HIV infections globally. The HIV-1 replication, reviewed extensively in 
Engelman and Cherepanov (2012) and depicted in Figure I-1 starts when the viral 
envelope (Env) glycoprotein engages host cell surface CD4 and CCR5 receptors. This 
leads to the fusion of the viral and cellular membranes, entry of the viral particle into the 
cell, reverse transcription of the viral genetic material and import into the cell nucleus. Viral 
mRNAs and the genome-length RNA, which are incorporated later into nascent virions, 
are generated by using host transcription machinery. The viral mRNAs drive the 
Figure I-1: Life cycle of HIV-1. 
Adapted from Engelman and Cherepanov 2012. 
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production of various viral proteins, which form the protein components of the viral particle. 
An infectious virion is generated by the subsequent budding and release of the viral 
particle from the host cell.    
In the infected host, the genome of HIV-1 also encodes several proteins whose 
function initially was deemed inessential for viral replication in various in vitro experiments 
with cell cultures. These proteins, including Nef, Vif, Vpu and Vpr, were therefore dubbed 
as “accessory”. However, the three decades of HIV-1 research gradually led to the 
realization that these proteins are directly involved in various aspects of the viral strategy 
to manipulate host innate and adaptive responses. In fact, we now realize that one cannot 
exaggerate the importance of the roles that these proteins play in antagonizing host 
factors that have evolved to safeguard the host cell against retroviral infections (Reviewed 
in Basmaciogullari and Pizzato (2014), and Guenzel et al. (2014). Here, I present a review 
of the recent advances in our knowledge about one particular “accessory” protein, Vpu 
and describe its interactions with various known host cell proteins and its vital contributions 
to the success of HIV-1 as a human pathogen. 
Viral protein U (Vpu) is the product of the vpu open reading frame of HIV-1 (Dube 
et al. , 2010a, Strebel et al. , 1988a). The protein is translated from a bicistronic mRNA 
which also encodes the envelope glycoprotein (Env) (Schwartz et al. , 1990). The env 
mRNAs of HIV-1 contain the vpu start codon followed by the open reading frame (ORF) 
coding the Env protein (Schwartz et al. , 1992). Env expression is thus a result of leaky 
scanning of the vpu start codon. Interestingly it is found in HIV-1, not in HIV-2 and most 
simian immunodeficiency viruses (SIVs) except those like SIVcpz (the chimpanzee-specific 
strain) that lie directly in the evolutionary path leading to HIV-1 (Gao et al. , 1999). It is a 
type III transmembrane protein of 77-86 amino acids in length depending on the group 
and subtype of HIV-1. For example, Vpu of strain HXB2 (belonging to group M, subtype 
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B) is 82 amino acids in length. It has a very short N-terminal domain, a transmembrane 
domain and a longer cytoplasmic domain which has two predicted α-helical domains 
separated by a hinge region (Figure 1). The hinge region contains two potential casein 
kinase II sites (Schubert et al. , 1992b).  
Comparisons of Vpu sequences from different geographical isolates have 
identified some conserved residues, which facilitated in delineating the protein’s various 
independent functions. For example, a tryptophan residue (W23) in the transmembrane 
domain was found to be invariant across all M group isolates along with L12, V14, I20, 
V22, I25, and I28, which are fairly conserved in most of them (McCormick-Davis et al. , 
2000). 
Two models describing 
potential interactions of one or both 
cytoplasmic helical domains with the 
surface of the plasma membrane 
have been suggested (Figure I-2). 
These two models need not be 
mutually exclusive as NMR 
characterization of the cytoplasmic domain of Vpu indicated that there is a great deal of 
structural flexibility in the cytoplasmic domain (Wittlich et al. , 2009a). A recently published 
full-length NMR structure of the denatured-renatured protein (Zhang et al. , 2015) indicates 
that the relative mobility of the cytoplasmic helices was dependent on the membrane 
mimetic environments used. In 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
proteoliposomes, the helices were flexible and could be either arranged in a linear or in a 
U -shaped orientation whereas in 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC) 
Figure I-2: Structural models of Vpu based on 
NMR and modeling data. 
(Andrew and Strebel, 2010) 
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micelles, where the backbone dynamics 
were more restricted and the cytoplasmic 
helices adopted well-defined U-shaped 
loop region between them.  
Vpu and its interactions with the CD4 
receptor. 
The T-cell CD4 receptors serve as 
the primary receptors for HIV-1 allowing it 
to gain entry to naïve uninfected cells. In 
infected host cells, HIV-1 effectively down-
regulates CD4. This serves the virus by 
effectively reducing multiplicity of infection 
on the one hand while efficient 
dissemination of virus progeny is ensured 
by minimizing recapture. HIV-1 evolved 
several independent and partially 
redundant mechanisms that down-regulate 
CD4  carried out by two the viral accessory 
proteins, Nef (Garcia and Miller, 1991) and 
Vpu (Willey et al. , 1992a). Nef is found in 
all mammalian lentiviruses that were 
described thus far. Vpu, however, is unique 
to HIV-1 and SIVcpz and is not found in HIV-
2 and many other SIV strains (Sauter et al. 
, 2009a).  While Vpu is not essential for viral propagation in cell cultures, it is important for 
Figure I-3: A model of the interactions 
between Vpu and CD4 at the ER membrane 
and the cytosol. 
Downregulation of CD4 is the result of 
multiple mechanisms. At least three such 
mechanisms may involve Vpu. (1) Direct 
interactions between Vpu and CD4 through 
their transmembrane domains leads to ER 
retention of the latter. (2) ER retention is also 
the result of indirect interactions between 
the two proteins via their cytosolic domains 
through interactions with “third party” 
cytosolic proteins (such as SCFβ-TrCP 
complex depicted here) (3) ER-retained 
CD4 is marked for degradation by 
ubiquitination mediated by conventional 
ERAD components (e.g. the VCP-UFD1L-
NPL4 complex) and specific interactions 
with proteins like the cytosolic SCFβ-TrCP 
complex recruited by the cytoplasmic 
domain of Vpu (Magadan and Bonifacino, 
2012, Magadan et al. , 2010). 
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virus infection in vivo. It is conceivable that Vpu was a major factor in the rapid evolution 
of HIV-1 from a relatively ineffective zoonotic pathogen to the successful pandemic-
causing agent as we know it today (Sauter, Schindler, 2009a). 
The involvement of Vpu with downregulation of CD4 receptors is multifaceted. Vpu 
binds CD4 and thereby causes it to be retained in the endoplasmic reticulum (ER). Vpu 
further induces CD4 degradation by exploiting a variant of the ER-associated protein 
degradation (ERAD) pathway (Magadan, Perez-Victoria, 2010).  Both the transmembrane 
and cytoplasmic domains of Vpu were implicated for CD4 binding and degradation 
(Tiganos et al. , 1998). Without diminishing the importance of other structural and 
functional attributes of this small protein, it is clear that Vpu interferes with plasma-
membrane presentation of CD4 through the interactions of their respective 
transmembrane domains (Magadan and Bonifacino, 2012).  For example, substituting the 
conserved tryptophan residue (Trp22 in NL4-3 strain Vpu sequence) in the 
transmembrane domain of Vpu results in a non-functional protein that is incapable of 
targeting CD4 for degradation through ERAD. On the other hand,  Val20 and Ser23 have 
also been identified as playing roles in CD4 retention in the ER (Magadan and Bonifacino, 
2012). Apart from this, the first membrane proximal a-helix in the cytoplasmic domain of 
Vpu has also been shown to interact with CD4 and the preservation its secondary structure 
has been shown to be important for binding and degradation of CD4 (Tiganos et al. , 
1997). The cytosolic domain of Vpu recruits the ubiquitination factors which ubiquitinate 
the cytoplasmic domain of CD4 at multiple lysine and serine/threonine residues to mark 
CD4 for proteasomal degradation and also further contribute in retention of CD4 in the ER 
(Magadan, Perez-Victoria, 2010). 
The interaction and the subsequent down-regulation of CD4 by Vpu also 
contributes significantly towards the maturation of the HIV-1 env gene product gp160 into 
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gp120 and gp41. The precursor gp160 protein is known to form complexes with CD4 at 
the ER (Bour et al. , 1991, Crise et al. , 1990, Jabbar and Nayak, 1990). This not only 
decreases the surface expression of mature CD4 but, also significantly reduces the 
proteolytic cleavage of gp160 into gp41 and gp120 (Jabbar and Nayak, 1990). 
Enhancement of intra-cellular processing of gp160 has been observed in the presence of 
Vpu where it is hypothesized that Vpu may facilitate the release of gp160 from the ER by 
destabilizing the CD4-gp160 complex (Kimura et al. , 1994, Willey et al. , 1992b). 
Vpu and BST-2 / tetherin. 
The transmembrane domain of Vpu is involved in its association with tetherin or 
BST2, an integral membrane protein serving as an anti-viral innate immune system 
component, whose importance is only starting to be appreciated (Douglas, Gustin, 2010b, 
Evans et al. , 2010a, Neil, 2013).  Tetherin functions to limit the escape of newly formed 
virions from cells infected by a variety of enveloped viruses like Ebola and HIV-1 (Douglas, 
Gustin, 2010b, Evans, Serra-Moreno, 2010a). It consists of a short N-terminal cytoplasmic 
tail, a transmembrane domain and an extra-cellular domain which is anchored to the 
membrane through a glycosyl-phosphatidylinositol (GPI) moiety (Kupzig et al. , 2003). 
They localize primarily in the cholesterol rich lipid raft regions of the plasma membrane as 
well as in the trans-Golgi network and the recycling endosomes (Kupzig, Korolchuk, 2003, 
Masuyama et al. , 2009). A fraction of the protein is normally targetted for lysosomal 
degradation through the Endosomal Sorting Complexes Required for Transport (ESCRT)- 
mediated pathway (Masuyama, Kuronita, 2009, Rollason et al. , 2007). 
Vpu mediated degradation of BST-2 has been shown to occur either by the 
lysosome (Douglas et al. , 2009, Iwabu et al. , 2009, Mitchell et al. , 2009) and/or by the 
proteasome (Goffinet et al. , 2009, Mangeat et al. , 2009). For either pathway, β-TrCP is 
indispensable for Vpu aided viral release pointing to a multi-modal mechanism of tetherin 
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antagonism by Vpu (Tervo et al. , 
2011). Vpu counteracts tetherin by 
its sequestration within the 
endomembrane system and 
interference with the normal 
intracellular trafficking of tetherin, 
leading to reduced levels of tetherin 
at the plasma membrane. This 
involves hijacking host machineries 
involved in the trafficking and 
turnover of tetherin (Mitchell, 
Katsura, 2009). Tetherin is then 
degraded by a ubiquitin-dependent 
mechanism in which 
phosphorylated Vpu recruits a SCFβ-
TrCP E3 ligase complex to 
ubiquitinate the cytoplasmic tail of 
tetherin at multiple residues and 
eventually targeting it for 
degradation (Douglas, 
Viswanathan, 2009, Goffinet, 
Allespach, 2009, Mangeat, Gers-
Huber, 2009, Mitchell, Katsura, 
2009, Tokarev and Guatelli, 2011). To target cell surface BST-2 to lysosomal degradation, 
Vpu interacts with the transmembrane domain of BST-2 (Iwabu, Fujita, 2009). This direct 
Figure I-4: Antagonism of BST-2 by Vpu. 
Schematic representation of Vpu mediated 
antagonism of BST-2 by the lysosomal degradation 
pathway (A) and the proteasomal degradation 
pathway (B). Adapted from (Douglas et al. , 2010b) 
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interaction is significant since Vpu fails to antagonize BST-2 derived from African green 
monkeys as well as chimeric human BST-2 containing a modified transmembrane domain 
(McNatt et al. , 2009, Rong et al. , 2009). A “dileucine” like motif in the second α-helix in 
the cytoplasmic domain of Vpu (McNatt et al. , 2013a) has been identified to be 
responsible for efficiently counteracting tetherin which potentially functions by displacing 
tetherin from the sites of viral assembly (Kueck and Neil, 2012a). In addition, NMR 
spectroscopy has also revealed a possible role of the C-terminal tryptophan in Vpu in 
displacing BST-2 from the sites of viral assembly in the plasma membrane by specifically 
interacting with membrane lipids (Lewinski et al. , 2015). Towards this view, it has indeed 
been shown that in T cells and primary macrophages, Vpu enhanced viral release is 
independent of intra-cellular depletion and surface down-modulation of of tetherin (Miyagi 
et al. , 2009).  
Disarming the Natural killer cells. 
Vpu has also been implicated in the down-modulation of Natural Killer (NK), T- cell, 
B-cell antigen (NTB-A) on infected T cells (Richard and Cohen, 2010, Shah et al. , 2010) 
as an evasion strategy against HIV-1 infected cell lysis by NK cells. NTB-A is found on 
NK, T and B cells and is a co-factor that regulates NK cell activation (Bottino et al. , 2001) 
in presence of an infection by homophilic interactions with the receptor on the target cell 
(Flaig et al. , 2004). In a mechanism completely different from the way in which Vpu down-
modulates CD4 and tetherin, Vpu brings about the retention of NTB-A in the Golgi 
apparatus by altering the glycosylation pattern in nascent NTB-A. This function has been 
traced to the second α-helical region of Vpu in its cytoplasmic domain (Bolduan et al. , 
2013a). Studies also show a role of the transmembrane domain of Vpu in this down-
modulation (Shah, Sowrirajan, 2010).   
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Vpu as a viroporin. 
In addition, based on similarities with other viral transmembrane proteins, Vpu has 
also been shown to possess monovalent cation selective ion-channel activity (Ewart et al. 
, 1996a, Schubert et al. , 1996), for example, potassium transport in Saccharomyces 
cerevisiae (Herrero et al. , 2013a) which, could potentially make the host membrane 
protein more permeable and aid in budding and release of nascent virions and thus has 
been categorized into a viroporin (Gonzalez and Carrasco, 2003). This activity was found 
to be strongly dependent on the sequence of amino acids in the transmembrane domain 
where a scrambled sequence of amino acids in the transmembrane domain of Vpu has 
been shown to complete abrogate the transport of ions (Schubert, Ferrer-Montiel, 1996). 
The ion-channel activity has also been recently demonstrated in vivo in potassium 
transport deficient bacteria (Taube et al. , 2014). In spite of these conclusive evidences, 
the functional significance of the role of Vpu as a viroporin in HIV life cycle has not been 
established (Strebel, 2014). 
A common feature of Vpu’s interaction with an array of host proteins is the fact the 
hydrophobic transmembrane domain serves an important functional role in this protein, 
apart from the soluble cytoplasmic domain. The dependence of the interactions of the 
transmembrane domain of Vpu with its binding partners on the positions of certain amino 
acids in the membrane spanning segment underlines the presence of an important 
structure-function relationship in the protein. Given the important role Vpu plays in the viral 
life-cycle, the study of these interactions could be exploited in designing efficient anti-viral 
drugs against HIV-1. An example of targeting the function of Vpu and sensitizing HIV-1 to 
BST-2 mediated host restriction was demonstrated recently where, 2-thio-6-azauridine 
was shown to restore cell surface expression of BST-2 in the presence of Vpu by limiting 
BST-2 ubiquitination (Zhang et al. , 2016). Similarly, amiloride derivatives like 5-(N,N-
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hexamethylene)amiloride and 5-(N,N-dimethyl)amiloride have been shown to block ion 
transport across the Vpu ion-channel and inhibit budding of HIV-1 virus like particles from 
HeLa cells (Ewart et al. , 2002). Drugs could also be designed to selectively target the 
binding of Vpu to host restriction factors. The reliability of such studies depends on the 
presence of reliable structural models of the protein. Even though a full length NMR 
structure of Vpu was recently published, further details of the structure with respect to its 
interactions with host cell factors are yet to be elucidated. Besides, although it is known 
that Vpu does exist in oligomeric states in vitro (Hussain et al. , 2007, Lu et al. , 2010, 
Maldarelli et al. , 1993), the physiological effects of this phenomena remains unknown. 
Aims and review of the dissertation. 
The challenges posed in solving the full-length structural model of Vpu, especially 
in terms of a high-resolution model using X-ray crystallography, due to the presence of the 
hydrophobic transmembrane domain has led to a somewhat “divide and conquer” 
approach amongst structural biologists. Taking into account the structural and functional 
significance of the transmembrane domain, as highlighted earlier, and its effect on the 
conformation and function of the cytoplasmic domain of this protein, the overall goal of this 
research was to solve a high-resolution structure of full-length Vpu using X-ray 
crystallography. Towards this, I intend to propose a suitable strategy to over-express Vpu 
heterologously. I would develop effective procedures to isolate the recombinant protein in 
a highly purified form and also subject it to various biophysical/ biochemical and functional 
characterizations to elucidate its suitability towards crystallization.  
Towards my overall goal, multiple strategies of heterologous over-expression of 
Vpu in bacterial expression system were employed. Expression, purification 
characterization of Vpu in fusion with bacterial proteins are discussed in Chapter II. Vpu 
could also be expressed in bacteria as a type I membrane protein, as discussed in Chapter 
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III. Furthermore, it was also shown that I was able to isolate satisfactory amounts of highly 
purified, functionally active, mono- disperse samples of the protein. Chapter IV describes 
my efforts to crystallize Vpu by extensive screening with a wide variety of crystallization 
conditions. Both in surfo and in cubo methods of crystallization were employed to this 
regard. Lastly, Vpu was also characterized in solution by Nuclear Magnetic Resonance 
(NMR) spectroscopy in the presence on different membrane mimetic environments, which 
are described in Chapter V.   
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II. Expression, purification and characterization of HIV -1 Vpu with N- terminal 
fusion proteins. 
Abstract 
Structural analysis of membrane proteins has traditionally been bottlenecked by 
the lack of sufficiently large amounts of pure, folded and functional membrane proteins. 
Hence multi-pronged protein expression approaches are necessary while attempting to 
produce membrane proteins for structural studies like X-ray crystallography. Vpu is a type 
III membrane protein of the HIV-1 which is expressed in host cells and is involved in virus 
release and propagation. It does so by interacting with an array of cellular factors by 
involving its transmembrane and cytoplasmic domain. Thus, there is exists an interesting 
structure-function relationship that is yet to elucidated. In this chapter, I describe my efforts 
to express Vpu in fusion with various fusion partners like the Bacilus subtilis Mistic and the 
Escherichia coli maltose binding protein (MBP). Expression of Vpu in fusion with these 
proteins posed significant challenges with regards to expression yield, purity, stability and 
mono-dispersity as discussed in the following sections. 
Introduction 
Genes encoding membrane proteins make up around 20-30% of the genome for 
both prokaryotes and eukaryotes. (Wallin and von Heijne, 1998). Many of these 
membrane proteins are drug targets and play key roles in diseases. But, given their low 
natural abundance, obtaining required quantities of membrane proteins for structural 
studies has been a challenge. Although prokaryotic expression systems are relatively 
robust and cost-effective than most eukaryotic systems, the successful over-expression 
of eukaryotic membrane proteins in gram-negative bacteria like Escherichia coli, has 
remained limited (Tate, 2001).  
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Heterologous over-expression of membrane proteins can be inefficient due to 
various reasons, such as, altered synthesis, targeting, insertion and folding characteristics 
of the over-expression host (Bowie, 2005, Goder et al. , 2004, Valent et al. , 1997). Some 
proteins could be dependent on specific chaperones to fold them in their functional 
conformation (Kota and Ljungdahl, 2005, Matsumoto et al. , 1987, Nagamori et al. , 2004), 
which may be absent in the chosen expression system. A vast number of eukaryotic 
membrane proteins rely on post-translational modifications like glycosylation for proper 
folding, stability and function (Helenius and Aebi, 2004).    
Viral protein U (Vpu) (Cohen et al. , 1988b, Strebel et al. , 1988b), is expressed by 
HIV-1 and its closest simian relative SIVcpz and is not found in most of the other known 
primate lentiviruses (e.g. HIV-2 and most SIVs) (Strebel, 2014, Yang et al. , 2010). Vpu is 
required for efficient virus propagation in vivo and may have been a factor in the rapid 
evolution of HIV-1 from a relatively ineffective zoonotic pathogen to the successful 
pandemic-causing agent that we know today (Andrew and Strebel, 2010, McCarthy and 
Johnson, 2014, Sauter et al. , 2009b, Yang, Lopez, 2010).  
Vpu is a 16-kDa type III transmembrane protein of 77-86 amino acids in length 
depending on the HIV-1 subtype. Vpu has a very short N-terminal extracellular domain, a 
transmembrane domain (TMD) and a longer cytoplasmic domain (CTD) which has two 
predicted α-helical regions separated by a hinge (Figure I-2). The hinge region contains 
two phosphorylation sites (Schubert et al. , 1992a) and is partially responsible for the 
flexibility of the CTD (Wittlich et al. , 2009b).  
Vpu plays a number of roles in promoting virion assembly and release (Dube et al. 
, 2010b, Roy et al. , 2014, Strebel, 2014). Vpu largely functions through protein-protein 
interactions to down-regulate key host-cell proteins (Andrew and Strebel, 2010). For 
example, Vpu interacts with the CD4 surface receptor through their respective 
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transmembrane domains, causing the retention of the receptor in the endoplasmic 
reticulum (Magadan and Bonifacino, 2012, Magadan, Perez-Victoria, 2010). 
Subsequently, the C-terminal domain of Vpu recruits ubiquitination factors that mark CD4 
for proteosomal degradation (Magadan and Bonifacino, 2012, Magadan, Perez-Victoria, 
2010). Similar mechanisms are also involved for the roles that the Vpu transmembrane 
domain and cytoplasmic domain play in the downregulation of tetherin or BST-2, an 
integral membrane protein that limits the escape of newly formed virions from cells 
infected by HIV-1 and other enveloped viruses (Douglas et al. , 2010a, Evans et al. , 
2010b, Kluge et al. , 2013, Kueck and Neil, 2012a). The C-terminal domain of Vpu directly 
functions to displace tetherin away from the sites of viral assembly in the host cell 
membrane (McNatt et al. , 2013b). In addition, Vpu belongs to a diverse group of small 
transmembrane viral proteins called viroporins that form homo-oligomeric ion channels. 
While Vpu’s channel activity has been well demonstrated (Ewart et al. , 1996b, Herrero, 
Monroy, 2013a), its physiological role is less clear (Strebel, 2014). 
The importance of Vpu for efficient assembly and egress of HIV-1 (Giese and 
Marsh, 2014, Jafari et al. , 2014, Pickering et al. , 2014) makes it a promising, but so far 
underexplored, therapeutic target. Developing its therapeutic utility requires establishing 
reliable structural information, which is the main focus of this thesis. The determination of 
a full-length structure is very important as the transmembrane domain influences the 
conformation, structure and dynamics of the C-terminal domain and vice versa.  
Given the challenges in obtaining a pure, folded, functional membrane protein 
samples discussed above, I wanted to explore alternative strategies of recombinantly 
expressing Vpu in bacteria which could supplement our efforts and provide a multi-
pronged approach towards crystallization and further structural studies on this protein. 
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Specifically, I explored the feasibility 
of over-expressing Vpu in the 
presence of cleavable fusion 
partners which could ultimately 
present us with a protein without any 
affinity tags. 
Certain fusion strategies 
were specifically designed to 
improve bacterial over-expression 
and correct folding of membrane 
proteins. Early during the project I 
was contacted by scientists working 
for the biotechnology company New 
England Biolabs to test a prototype 
they have developed for over-
expression of membrane protein they developed for E. coli. The expression plasmid 
consists of a N-terminal wild-type M13 phage major coat protein (P8), with the hydrophobic 
residues in its transmembrane domain being an ideal target for the Signal recognition 
particle (SRP). The P8 open reading frame (ORF) was extended by the E. coli Signal 
peptidase which provides for a second transmembrane domain (TM2) to localize the 
fusion junction in the periplasmic space of the bacteria. The chitin binding domain located 
in the cytoplasmic loop, between the two transmembrane segments, provided for an 
affinity and/or detection tag. The Enterokinase (ek) protease cleavage site was engineered 
at the fusion junction to cleave the protein of interest from the rest of the fusion (Luo et al. 
, 2009). Apart from that, it also utilizes efficient charge distribution to ensure a predictable 
Figure II-1: A schematic representation of the 
p8CBDek system and its membrane orientation. 
The P8 transmembrane segment brings about 
efficient membrane insertion via the SRP pathway. 
The chitin binding domain (CBD) can serve as an 
affinity tag. The protein of interest, fused 
downstream can be proteolytically cleaved using 
enterokinase. (Adapted from Luo et al., 2009). 
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topology of the membrane protein of interest in the bacterial inner membranes (Figure 
II-1).  
The membrane-integrating sequence for translation of integral membrane protein 
constructs (Mistic) (Roosild et al. , 2005) is a 110 KDa protein fragment derived from 
Bacillus subtilis which has been shown to yield high levels of properly folded integral 
membrane proteins in the E. coli membranes (Dvir and Choe, 2009, Kefala et al. , 2007, 
Lee et al. , 2008, Liu et al. , 2008, Roosild et al. , 2006, Xu et al. , 2013). Although it is 
fairly hydrophilic with acidic residues making up most of the surface area of the four-helix 
bundle protein, it has been shown to associate tightly with the membranes when 
recombinantly expressed in E. coli. Intriguing is also the fact that none of the four helices 
are predicted to be transmembrane segments and yet it aggregates in an aqueous 
environment without the presence of detergents (Dvir et al. , 2009).  
The maltose binding protein (MBP) from E. coli has been used as a fusion partner 
to increase the solubility of target proteins and also to promote their proper folding (Kapust 
and Waugh, 1999, Korepanova et al. , 2007, Maina et al. , 1988, Nallamsetty et al. , 2005, 
Nallamsetty and Waugh, 2007). The 40-kDa maltose-binding protein (MBP) is encoded by 
the mal E gene of E. coli K12 strain (Duplay and Hofnung, 1988). Because MBP is 
exported across the inner bacterial membrane to the periplasmic space (Bassford, 1990, 
Bedouelle et al. , 1980), by fusing its C-terminus to a membrane protein, MBP it could 
facilitate the efficient insertion of the cargo protein into the E. coli membrane. Vectors that 
facilitate the expression and purification of foreign peptides in E. coli by fusion to MPB 
were first described in 1988 (di Guana et al. , 1988). MBP also allows for an additional 
affinity tag for purification by virtue of its affinity to amylose (Kellermann and Ferenci, 
1982), which when used in combination with other affinity tags, such as poly-histidine, 
provide flexibility in designing purification strategies. Moreover, it has also served as an 
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excellent crystallization partner which has resulted in over 100 structures of MBP with 
various proteins so far (Waugh, 2016).   
In this chapter, I describe my efforts in expression, purification and characterization 
of Vpu in fusion with Mistic and MBP. Attempts to express Vpu as a C-terminal fusion of 
P8CBDek was unsuccessful since I could not obtain any levels of protein expression using 
that strategy. 
Materials and Methods 
Target selection and gene optimization. 
The sequence of HIV- 1 group M subtype B strain HXB2 Vpu was used. 
Unfavorable codons for each 82 amino acids in length were replaced using the E. coli 
codon usage table (Sharp and Li, 1987). The vpu gene optimized for expression in E. coli 
was synthesized by overlap extension PCR. Overlapping oligonucleotides, oTMs 638 – 
645 (Table II-1) of sizes ranging from 30-40 bases were ordered from Integrated DNA 
Technologies. The first round of PCR (Roche High Fidelity PCR Kit; cat# 11732641001) 
to assemble to the gene was done for 25 cycles (initial denaturation: 94 ºC for 2 min; 
denaturation: 94 ºC for 15 s; annealing: 55 ºC for 30 s; elongation 72 ºC for 30 s; final 
elongation: 72 ºC for 7 min) and was followed by a second round of PCR with external 
primers oTMs 646 and 647 for 40 cycles for amplification (initial denaturation: 94 ºC for 2 
min; denaturation: 94 ºC for 15 s; annealing: 58 ºC for 30 s; elongation 72 ºC for 30 s; final 
elongation: 72 ºC for 7 min). The PCR product was first cloned into a TOPO-TA 
intermediate cloning vector (Invitrogen; cat# 450641). 
Cloning of E. coli optimized vpu into various expression vectors. 
The vpu gene sequence of HIV-1 group M subtype B strain HXB2 Vpu, which was 
optimized for expression in E. coli, as detailed above, was first engineered to have flanking 
TEV protease cleavage sites by performing a PCR (initial denaturation: 94 ºC for 2 min;  
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Table II-1: DNA primers used towards the creation of E. coli optimized vpu gene and pTMs 
794, 869 and 975. 
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denaturation: 94 ºC for 15 s; 
annealing: 60 ºC for 30 s; elongation 
72 ºC for 30 s; final elongation: 72 ºC 
for 7 min) with oTMs 657 and 658 
(Table II-1) for 30 cycles of 
amplification and then ligated to a 
Gateway compatible TOPO TA 
vector (ThermoFisher Scientific, 
cat# K250020SC) to generate a 
Gateway donor vector. The vpu 
gene was then cloned into an 
expression vector by LR 
recombination reaction, following 
product protocol, and transformed 
into DH5α electro-competent cells. The resulting bacterial colonies were screened using 
colony screen PCR using gene specific primers oTMs 662 and 663, which would result in 
a fusion of Vpu with Mistic (pTM794, Figure II-2), which was also confirmed by DNA 
sequencing with oTMs 662 and 663.  
For the creation of a cleavable fusion of MBP and Vpu, a TEV protease cleavage 
site was engineered at the 5’ end of the vpu gene by performing PCR (initial denaturation: 
94 ºC for 2 min; denaturation: 94 ºC for 15 s; annealing: 55 ºC for 30 s; elongation 72 ºC 
for 30 s; final elongation: 72 ºC for 7 min) with primers oTMs 657 and 663 for 30 cycles of 
amplification. The PCR product was ligated to a Gateway compatible TOPO TA vector as 
mentioned above and then the gene was recombinantly transferred to an expression 
vector, and transformed into DH5α electro-competent cells. The resulting bacterial 
Figure II-2: The pTM794 expression vector. 
Expression of the Mistic-Vpu fusion is driven by the 
T7 promoter. The fusion contains TEV protease 
cleavage sites to isolate Vpu from Mistic and 
purification tags. 
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colonies were screened using 
colony screen PCR using gene 
specific primers oTMs 662 and 663 
to generate a MBP-TEV-Vpu 
expression vector (pTM869, Figure 
II-3), which was also confirmed by 
DNA sequencing with oTMs 662 and 
663.  
Towards manufacturing a 
variant of a cleavable fusion of MBP 
and Vpu, with a shorter linker 
between the two proteins, a 
PreScission protease cleavage site 
(PPCS) was engineered at the 5’end 
of the vpu gene by performing a PCR (initial denaturation: 94 ºC for 2 min; denaturation: 
94 ºC for 15 s; annealing: 58 ºC for 30 s; elongation 72 ºC for 30 s; final elongation: 72 ºC 
for 7 min) with primers oTMs 903 and 905 for 30 cycles of amplification. These primers 
were also responsible for adding flanking NcoI and XhoI sites on the PCR product. The 
PCR product was first cloned into a TOPO-TA intermediate cloning vector (Invitrogen; cat# 
450641). was excised from this intermediate vector by digestion with NcoI and XhoI 
restriction enzymes (NEB; cat# R0585S). The same pair of restriction enzymes were also 
used to linearize the pET26(b) vector containing the mbp gene preceding the pelB signal 
sequence. The restriction digestion reactions were analyzed by agarose gel 
electrophoresis and the desired DNA bands were excised and purified using a QIAquick 
gel extraction kit (Qiagen; cat# 28704). The gene was ligated to the backbone by 
Figure II-3: The pTM869 expression vector. 
Expression of the MBP-TEV-Vpu fusion is driven by 
the T5 promoter. The fusion contains TEV protease 
cleavage sites to isolate Vpu from MBP and extra 
amino acids translated from the Gateway 
recombination sequences. 
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performing a T4 DNA ligase reaction 
(Promega; cat# M1801) and 
transformed into DH5α electro-
competent cells. The resulting 
bacterial colonies were screened 
using colony screen PCR using 
gene specific primers oTMs 662 and 
663 and plasmid specific primers, 
oTMs 856 and 857. DNA 
sequencing using oTMs 856 and 
857 was used to verify the final 
expression clone, pTM975 (Figure 
II-4).  
Expression of Vpu with its fusion partners. 
The expression of the Mistic-Vpu and MBP-PPCS-Vpu fusion along with the metal 
affinity tags was driven by a T7 promoter and MBP-TEV-Vpu was driven by a T5 promoter. 
The expression vectors were electroporated into BL21(DE) cells. For protein expression, 
overnight cultures of BL21(DE) cells containing the respective expression vectors were 
grown in LB media supplemented with 100 μg/mL ampicillin for pTMs 794 and 869 and 
100 μg/mL kanamycin for pTM975 and was used to inoculate a fresh LB media with 100 
μg/mL ampicillin for pTMs 794 and 869 and 50 μg/mL kanamycin for pTM975 in a 1:100 
dilution. The cultures for expression were shaken at 180 rpm at 37 ºC till an OD600 of 
approximately 0.4. BL21- pTMs 794 and 869 cultures were then moved to 15 ºC and were 
incubated for 30 min with 180 rpm shaking. Finally, the cultures were induced for 
expression with 0.1 mM IPTG. In case of BL21- pTM975 cultures, expression was induced 
Figure II-4: The pTM975 expression vector.  
Expression of the MBP-PPCS-Vpu fusion is driven by 
the T7 promoter. The fusion contains PreScission 
protease cleavage sites to isolate Vpu from MBP. 
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at 30 ºC at an OD600 of approximately 0.5 with 0.2 mM IPTG. For standardization of 
expression conditions, 5 mL of culture were collected at various time points after IPTG 
induction and pelleted by centrifugation at 4000 ×g, 4 ºC for 5 min. For detergent extraction 
screens and purifications, cultures were pelleted at 4 hr post induction for BL21- pTMs 
794 and 869 at 5000 ×g, 4 ºC for 15 min. In case of BL21-pTM975, the cultures were 
pelleted after 16 hr post-induction, allowing for over-night expression of the recombinant 
protein. All cell pellets were stored at -80 ºC until further use. 
Membrane isolation 
Cell pellets from 4 L worth of culture (approximately 12 g) were resuspended in 
100 mL of ice-cold phosphate buffer saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) supplemented with EDTA-Free SIGMAFAST™ 
Protease Inhibitor Cocktail tablets, to prevent protein degradation. The cells were lysed by 
passing twice through a microfluidizer (Microfluidics Microfluidizer). The lysate was 
collected and centrifuged at 36,000 ×g for 30 min. The insoluble fraction was washed once 
by repeated resuspension (30 mL of ice-cold PBS with protease inhibitor cocktail) and 
centrifugation. If not immediately used, the pellet was frozen at -80 ºC. 
Detergent extraction 
Aqueous and non-aqueous fractions from 500 mL cultures were prepared as 
described above, induced for expression and cells were harvested as pellets as mentioned 
previously. The pellet containing the non-aqueous proteins was re-suspended in 25 mL of 
PBS-PI buffer. Samples (4 mL) were then subjected to detergent extraction by addition of 
the following detergents to final concentration of 1% (w/v): n-dodecyl-β-D-maltoside 
(βDDM, Glycon Biotech; cat# D97002C), n-decyl-β-D-maltoside (βDM, Anatrace; cat# 
D322), 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS, Mclab; 
cat# DCPS101), n-octyl β-D-glucopyranoside (OG, Glycon Biotech; cat# D97001C), n-
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dodecylphosphocholine (DPC, Anatrace; cat# F308S) and n-dodecyl-N,N-dimethylamine-
N-oxide (LDAO, Anatrace; cat# D360). The samples were left overnight at 4 ºC with 
agitation at 200 rpm and centrifuged at 36,000 ×g for 30 min at 4 ºC on the following day 
and the supernatant was collected as the detergent soluble fraction. The fractions were 
analyzed by SDS-PAGE followed by Coomassie staining and western blot. 
For large-scale extractions from 4 L cultures, the pellet, containing the membrane 
fraction, was fully re-suspended in 200 mL PBS supplemented with EDTA-Free 
SIGMAFAST™ Protease Inhibitor Cocktail tablets. βDDM was used for solubilization at a 
final concentration of 1% (w/v). The protein was extracted and at 4 ºC overnight with 
agitation at 200 rpm. The detergent soluble fraction was obtained by collecting the 
supernatant after centrifugation at 36,000 ×g for 30 min at 4 ºC. 
Purification 
A gravity driven column (Biorad Econo-column) containing 25 mL bed volume of 
TALON metal affinity resin (Clontech laboratories Ltd; cat# 635503) was equilibrated with 
binding buffer (PBS500 (8.1 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 500 mM NaCl, 
pH 7.5) supplemented with 0.05% βDDM). Detergent (βDDM)-soluble fraction containing 
the Mistic-Vpu or MBP-TEV-Vpu fusion protein were loaded onto the Talon resin and passed 
twice. Column was washed with 10 bed volumes of buffers such as twice with PBS500 (WI 
and WII), once with PBS + 0.05% βDDM (WIII) and once with PBS, 0.05% βDDM, and 
5mM Imidazole (WIV). Elution was done with three column volumes of PBS, 0.05% βDDM, 
supplemented with 250 mM Imidazole. 
The eluted sample was concentrated by 30 kDa molecular weight cutoff (MWCO) 
concentrators (Millipore; cat# UFC903008) to approximately 1/15th its original volume. 
Concentrated samples were further purified by size exclusion chromatography (GE Life 
sciences, Superdex 200 10/300 GL; column volume: 24 mL; fluid phase: 8 mL) using a 
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fast pressure liquid chromatography instrument (FPLC, Pharmacia, Äkta Explorer). The 
running buffer contained 20 mM HEPES pH 7.5, 100 mM NaCl and 0.05% βDDM in case 
of Mistic-Vpu and PBS pH 7.4, 5% glycerol and 0.05% βDDM in case of MBP-TEV-Vpu. For 
preparatory separations, a 1 mL sample of concentrated Vpu was loaded onto the S 
column and chromatography was performed at a flow rate of 0.5 mL/min. The protein 
elution was detected by absorption at 280 nm.  
To purify MBP-PPCS-Vpu, a gravity driven column (Biorad Econo-column) containing 
30 mL bed volume of TALON metal affinity resin was equilibrated with binding buffer (20 
mM HEPES pH 7.5, 500 mM NaCl, 0.02% βDDM, 5 mM imidazole). The sample was then 
loaded onto the column, and passed twice. The column was washed with ten bed volumes 
of wash buffers containing various combinations of salt and imidazole, for example, 20 
mM HEPES, pH 7.5 with 500 mM NaCl (Wash I), 500 mM NaCl, 0.02% βDDM (Wash II), 
250 mM NaCl, 0.02% βDDM (Wash III) and 250 mM NaCl, 0.02% βDDM, 5% glycerol, 10 
mM imidazole (Wash IV) to remove weakly bound proteins. Tightly bound proteins were 
eluted by application of 3 bed volumes of elution buffer (20mM HEPES pH 7.5, 250 mM 
NaCl, 0.02% βDDM, 5% glycerol, 300 mM imidazole). 
The eluted sample was concentrated by 100 kDa molecular weight cutoff (MWCO) 
concentrators (Millipore; cat# UFC910024) to approximately 20 times its original volume. 
Concentrated samples were further purified by size exclusion chromatography (GE Life 
sciences, Superdex 200 10/300 GL; column volume: 24 mL; fluid phase: 8 mL) using a 
fast pressure liquid chromatography instrument (FPLC, Pharmacia, Äkta Explorer). The 
running buffer contained 20 mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM and 5% 
glycerol. 
Protease digestion. 
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The heterologous Tobacco Etch Virus (TEV) protease was expressed from the 
pRK793 (Addgene, cat# 8827) plasmid, expressing a highly stable mutant of the protease 
(S219V, (Kapust et al. , 2002, Kapust et al. , 2001). The plasmid was electroporated in 
BL21(DE) cells and was expressed a self-cleaving fusion with the maltose binding protein 
by inducing a mid-logarithmic phase culture with 1 mM IPTG at 20 ºC. The cultures were 
harvested after 4 hr post- induction and lysed as mentioned above. Recombinant TEV 
protease was purified over a Talon metal affinity resin by first, equilibrating the resin with 
the binding buffer (20 mM TRIS pH 8, 500 mM NaCl and 5 mM Imidazole). The cell lysate 
was passed twice and washed with 30 column volumes of the binding buffer and was 
eluted in two column volumes of the same buffer, with 300 mM imidazole. The purified 
protease was stored at a concentration of 1 mg/mL in a buffer consisting 50 mM TRIS pH 
7.5, 1 mM EDTA, 5 mM DTT, 50% glycerol and 0.1% Triton X-100 at -20 ºC. For cleavage, 
the protease was used up to an amount of 1 mg per the amount of target fusion protein 
obtained per 1L of culture. 
PreScission Protease (GE Healthcare, cat# 27-0843-01) was used up to amounts 
of 100 U per the amount of fusion protein obtained per 1L of culture. 
Gel electrophoresis, staining and western blots 
 SDS-PAGE using TRIS - based buffers (25 mM TRIS, 200 mM glycine and 3.5 
mM SDS) was performed in a Biorad Mini-PROTEAN Tetra Cell. Following 
electrophoresis, gels were stained by coomassie brilliant blue, subjected to silver staining, 
or processed for immuno-blotting. For immuno-blotting, the acrylamide gel was first rinsed 
with water and equilibrated in a non-denaturing buffer (25 mM TRIS base and 200 mM 
glycine). The nitrocellulose membrane (Biorad; cat# 162-0112) was also equilibrated in 
the non-denaturing buffer. The gel and the membrane were sandwiched between extra-
thick blot filter papers (VWR; cat# 28298-014) soaked in the non-denaturing buffer and 
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proteins were electro- blotted for 15 min at 15 V using a Biorad Transfer-blot SD Semi-dry 
Transfer Cell. Following an hour long blocking in PBSTM (PBS, 0.05% Tween 20 and 5% 
dry milk), the nitrocellulose membrane was further incubated in the presence of the 
appropriate primary antibody. The membrane was then washed 3×15 min in PBST (PBS 
and 0.05% Tween 20) prior to a one-hour incubation with the appropriate secondary 
antibody conjugated to horseradish peroxidase. Following additional 3x 15 min washes, 
the nitrocellulose membrane was then soaked in Immunocruz western blotting luminol 
reagent (Santa Cruz Biotechnology; cat# sc-2048), exposed to a chemiluminescence 
sensitive film (GE Heathcare; cat# 28906838) for the optimum time of exposure and the 
film was developed with a Konica SRX-101A system. Anti- Vpu polyclonal antibody, raised 
in rabbits, was kindly provided by the NIH’s AIDS Reagent Program and was used at a 
dilution of 1: 30,000. Monoclonal antibodies against the poly-histidine tag (Sigma, cat# H-
1029), raised in mouse, was used at a dilution of 1: 5,000. Goat anti-rabbit IgG - HRP 
(Santa Cruz Biotechnology; cat# sc-2923) and rabbit anti-mouse IgG-HRP (Sigma A-
9044) were used at a dilution of 1:10,000 in PBSTM. 
Dynamic light scattering 
Dynamic light-scattering (DLS) measurements were performed using a NaBiTec 
GmbH setup comprising a SpectroSize 302 (Molecular Dimensions) in combination with 
an S6D microscope (Leica). The purified protein sample was concentrated to 10 mg/mL 
as described earlier was illuminated in a 2 μL hanging drop using a 24-well crystallization 
plate (VDX Greased Plate, Hampton Research) covered with siliconized-glass circular 
cover slides (22 mm; Hampton Research). The well itself was filled with 400 μL S running 
buffer. Prior to the measurement, the protein solution was centrifuged at 18000 ×g, 30 
min, 4 ºC to remove possible dust and other suspended particles. All measurements were 
done at 20 ºC. Ten consecutive measurements, each with an integration time of 20 s, were 
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averaged. Hydrodynamic size of the 
particles was estimated with the 
instrument software using the 
following parameters: refractive 
index 1.33, viscosity 1.006, shape 
factor 1.0 and hydrated shell 0.2 nm. 
Results and Discussion 
Gene Optimization.  
Vpu is an important 
accessory protein involved in HIV – 
1 pathogenesis. Furthermore, the presence of a transmembrane domain with an intriguing 
structure – function relationship makes it an attractive target for structural studies. In this 
study, unfavorable codons from the native Vpu gene from subtype B HIV – 1 were 
removed and were replaced by codons widely used in the E. coli expression system 
(Figure II-5). Codon optimization to increase yield and stability of the target recombinant 
protein has been successfully used in the laboratory for the expression of human 
butyrylcholineesterase (Geyer et al. , 2010) and HIV-1 Gag/dgp41 virus like particles 
(Kessans et al. , 2013) in Nicotiana benthamiana. Codon optimization of the vpu gene has 
been shown to improve its mRNA stability and magnitude of expression in HeLa cells 
when transcribed under the control of a CMV promoter (Nguyen et al. , 2004). Upon 
analysis, it was seen that the native vpu gene is composed of significantly unfavorable 
codons with respect to the E. coli codon usage patterns with a codon adaptation index 
(CAI) of 0.101.  Removal of these unfavorable codons and replacing them with codons 
more suited to the E. coli codon usage patterns resulted in an increase of the CAI to 0.916. 
In the human genome, there is a weak positive correlation between frequency of optimal 
Figure II-5: Codon Usage analysis of Vpu. 
Codon usage analysis of the native HIV-1 vpu gene 
in E. coli (red) and H. sapiens (blue). The vpu gene 
optimized for expression in E. coli (black). 
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codons and levels of gene expression (Lavner and Kotlar, Urrutia and Hurst, 2003). It is 
interesting to observe that the frequency of non-optimal codons is significantly higher at 
the region of the native gene encoding the N – terminal part of the protein. There is 
evidence to suggest that usage of low frequency codons within a coding sequence could 
be indicative of a genetic instruction that regulates the rate of protein synthesis. This 
phenomena could facilitate the formation of some secondary and/or tertiary structure in 
the nascent polypeptide (Marin, 2008, Purvis et al. , 1987). But, the idea of the action of 
codon usage bias to improve translational efficiency remains unconfirmed in mammals 
(Kanaya et al. , 2001).  On the other hand, in unicellular organisms like E. coli, there is a 
strong correlation between the most frequently used codons and the abundance of tRNAs 
(Ikemura, 1981, 1982).Thus, the codon usage pattern can greatly influence the rate and 
efficiency of translation in E. coli (Robinson et al. , 1984, Sorensen et al. , 1989), leading 
to enhanced expression levels of the recombinant membrane protein. This E. coli 
optimized gene was cloned into the expression vectors discussed in this chapter. 
Expression in E. coli.  
Bacterial cells harboring pTMs 794, 869 and 975 were grown till mid logarithmic 
phase and induced with IPTG for protein expression. Expression conditions were 
optimized in regard to host strain, culture growth temperature and shaking during 
induction, length of induction period. A test for induction period length is shown in Figure 
II-6 in regard to the fusion of Vpu with MBP and Mistic. Best expression was obtained 
using the strain BL21(DE3) while other expression strains such as C41, C43, C41PlyS 
and C43PlyS were erratic in their expression patterns and were not reproducible over time. 
Expression at 15 ºC for Mistic-Vpu and MBP-TEV-Vpu resulted in negligible leaky 
expression from all these constructs as seen when expression is analyzed at various time 
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points by SDS-PAGE followed by 
immunoblotting with anti-Vpu rabbit 
antiserum  (Figure II-6). All the 
constructs produced useful 
quantities of Vpu with its fusion 
partners. Higher amounts of 
expression were observed in case of 
Mistic-Vpu than the fusion of Vpu 
with MBP. This could be due to the 
fact that MBP is a larger protein than 
Mistic and thus imposed a larger 
metabolic cost on the bacterial cells. 
Detergent extraction screen.  
Since the transmembrane 
domain of Vpu, which otherwise 
targets the protein into host cell 
membranes in natural conditions, is 
unable to target the protein 
effectively in bacterial cells (Ma et al. 
, 2002), I relied on its fusion partners 
to efficiently target and integrate the 
protein into the bacterial inner 
membranes. To have a sense of the 
localization of the protein in the cells 
and to select the optimal detergent 
Figure II-6: Expression time-course of Vpu with 
Mistic and MBP. 
Expression of Mistic-Vpu (A) MBP-TEV-Vpu (B) and 
MBP-PPCS-Vpu (C) fusion in BL-21 cells as a function 
of induction time. Samples from control cells (BL21, 
NC) and cells harboring respective plasmids were 
induced by IPTG and harvested at the indicated 
time points (in hr post induction, ON, overnight or 
~12 hr) and lysed in SDS sample buffer. Proteins in 
samples were resolved by SDS/PAGE and 
subjected to immunoblot analysis, probed with anti- 
Vpu. The arrows indicate the position of bands 
corresponding to the protein of interest in each 
case. 
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extraction conditions I conducted a small-scale detergent extraction screen for all the 
fusion proteins with mild maltoside detergent βDDM and βDM, zwitterionic detergents like 
DPC and LDAO and shorter chained detergents such as OG and CHAPS. The extraction 
was done at the indicated temperature (Figure II-7). The Mistic-Vpu fusion was found in 
the non-aqueous fraction and was efficiently extractable by both of the maltosides and 
Figure II-7: Detergent extraction screen of Vpu with Mistic and MBP. 
Detergent extraction screen for Mistic-Vpu at 4 ºC (A) and 25 ºC (B). Cells were lysed by 
passage through a microfluidizer, the homogenate was centrifuged to separate water-
soluble proteins from the insoluble fraction (Lane 1). The pellet was resuspended in buffer 
containing the indicated detergents bDDM (Lane 2), bDM (Lane 2), CHAPS (Lane 4), 
DPC (Lane 5), LDAO (Lane 6) and OG (Lane 7) at 1% w/v. Supernatant was collected 
following centrifugation and proteins were resolved by SDS-PAGE followed by 
immunoblot analysis, probed with anti-Vpu.  
Similar procedure was followed for detergent extraction screen for MBP-TEV-Vpu (C) and 
MBP-PPCS-Vpu (D). Cells were lysed by passage through a microfluidizer, the homogenate 
was centrifuged to separate water-insoluble (lane 1) proteins from the soluble fraction 
(lane 2). The pellet was resuspended in buffer containing the indicated detergents bDM 
(Lane 3), bDDM (Lane 4), CHAPS (Lane 5), OG (Lane 6), LDAO (Lane 7) and DPC (Lane 
8) at 1% w/v. Supernatant was collected following centrifugation and proteins were 
resolved by SDS-PAGE followed by immunoblot analysis, probed with anti-Vpu. Black 
arrows indicate the protein of interest. 
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zwitterionic detergents (Figure II-7 A and B). The short-chained detergents, with relatively 
inflexible hydrophobic tails, like OG and CHAPS were relatively weak in extracting Mistic-
Vpu from bacterial membranes and temperature seemed to have no drastic effect in 
helping the cause.  
The MBP-Vpu fusion expressed from BL21-pTM 869 (MBP-TEV-Vpu) was targeted 
by its native signal peptide at the N-terminal region, which targets MBP to the periplasmic 
space of the bacteria (Bedouelle, Bassford, 1980). I observed that the fusion protein 
fractionated evenly into both the aqueous and the non-aqueous fractions (Figure II-7C). 
Why would a fusion protein containing a hydrophobic alpha helical domain be found in the 
aqueous fraction? A possible explanation could be that the translocon-facilitated insertion 
of the over-expressed membrane protein into the membrane is constrained either by the 
finite membrane surface area (Drew et al. , 2003), or by the capacity of the translocation 
machinery to keep up with the translation process. Either way the fusion protein ends up 
accumulating in the cytoplasm. The bacteria often accumulate such proteins in the form 
of dense, insoluble aggregates (inclusion bodies). However, MBP is known to prevent the 
aggregation of its fused cargo and maintain it in solution even at high concentrations. In 
fact, this is one of the main reason why MBP is considered to be such a successful fusion 
partner. It is therefore conceivable that MBP prevents aggregation of MBP-TEV-Vpu as 
inclusion bodies. Since a membrane protein in an aqueous environment is not likely to 
maintain its functional conformation, I proceeded to extract the protein in the non-aqueous 
fraction with detergents. In this case, it is observed that the protein is extractable by the 
whole panel of detergents. In view of the compatibility with the down-stream processes, 
bDDM was the detergent of choice. 
On the other hand, the MBP-Vpu fusion protein obtained from BL21-pTM 975 
(MBP-PPCS-Vpu), which is targeted by the PelB signal peptide is exclusively found in the 
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non-aqueous fraction (Figure II-7D). 
This protein was extractable with a 
wide range of detergents, except 
OG which, performed poorly. Again, 
taking in to consideration the 
suitability of the detergents towards 
subsequent experiments, bDDM 
was used for all future purposes.       
Large-scale extraction purification of 
Mistic-Vpu.  
Cells harboring pTM 794 
were induced for 3 h post-induction 
with 0.1 mM IPTG, lyzed by passage 
through a microfluidizer, centrifuged 
to remove water-soluble proteins 
and the pellet was subjected to 1% 
bDDM extraction at 4 ºC overnight 
and centrifuged to separate bDDM-
soluble (supernatant fluid) and 
insoluble (pellet) fractions. The 
detergent-soluble protein fraction 
was subjected to metal affinity 
chromatography purification (Figure 
II-8). I observed that the fusion protein was efficiently bound to the affinity resin with little 
or no loss of protein in the flow-through and the washes. The presence of multiple histidine 
Figure II-8: Talon metal affinity chromatography 
purification of Mistic-Vpu.  
Detergent (βDDM)-soluble fraction containing the 
Mistic-Vpu fusion protein were loaded onto a Talon 
resin pre-equilibrated with PBS500 (8.1 mM 
Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 500 mM 
NaCl, pH 7.5) supplemented with 0.05% βDDM 
(lane1, flow through). Column was washed twice 
with PBS500 (W1, lane 2 and W2, lane 3), once with 
PBS + 0.05% βDDM (W3, lane 4) and once with 
PBS, 0.05% βDDM, and 5mM Imidazole (W4, lane 
5). Elution was done with PBS, 0.05% βDDM, 250 
mM Imidazole (E, lane 6). Protein fractions were 
subjected to SDS-PAGE followed by silver staining 
(A) and immunoblot analysis, probed with anti-Vpu 
(B). Black arrow indicates Mistic-Vpu. 
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tags in the construct probably was 
instrumental to achieve such 
excellent binding. The desired 
protein, eluting with high 
concentrations of imidazole, was 
seen to be containing some higher 
molecular weight contaminants.  
Because the Mistic protein 
largely resisted attempts to 
crystallize it, was mostly 
characterized by NMR spectroscopy 
(Dvir, Lundberg, 2009, Roosild, 
Greenwald, 2005), I anticipate that 
the Mistic-Vpu fusion protein would 
not be an ideal candidate for 
crystallization. My intention was 
therefore to cleave the protein from 
Vpu by complete digestion with TEV 
protease and subject the cleaved 
products to a second round of metal 
affinity purification. The 
contaminants co-eluting with the 
Mistic-Vpu fusion is predicted to elute with the Mistic protein containing the poly-histidine 
tag in this second round of affinity purification whereas relatively pure Vpu should be found 
in the flow-through and washes.  
Figure II-9: Site specific proteolytic cleavage of 
Mistic-Vpu.  
Affinity-purified Mistic-Vpu (lane 1) was subjected 
to digest with TEV protease (lane 2) followed by a 
second-round of metal-affinity chromatography. 
Unbound proteins were collected (lane 3), and the 
column was washed with 10 CV of wash buffer 
thrice (lanes 4-6). Tightly bound proteins were 
eluted with a higher concentration of imidazole 
(lane 7). Protein fractions were subjected to SDS-
PAGE followed by silver staining (A) and 
immunoblot analysis, probed with anti-Vpu (B). 
Black arrow indicates cleaved Vpu. 
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The TEV protease is a site-
specific protease that has a seven-
amino-acid recognition site; E-X-X-
Y-X-Q-S. Cleavage occurs between 
the conserved glutamine and serine 
(Dougherty et al. , 1989) where, X 
can be various amino acid residues 
but not all are tolerated. The optimal 
sequence for cleavage is E-N-L-Y-F-
Q-S (Carrington and Dougherty, 
1988, Dougherty et al. , 1988) was 
used in between the fusion proteins 
involving Vpu.  Its high specificity, its 
activity on a variety of substrates, and the efficient cleavage at low temperature were the 
major reasons why I chose to use the TEV protease to removing the Mistic tag from our 
fusion protein (Parks et al. , 1994). The efficiency of cleavage depends on both the tag 
and the protein fused to the carboxyl terminus of the TEV cleavage site and is difficult to 
predict a priori and has to be determined experimentally. 
Thus, following the affinity chromatography step, the eluate was concentrated and 
then subjected to digestion with the TEV protease (Figure II-9). The fusion protein was 
difficult to cleave to completion. In fact, even in the presence of high concentrations of 
TEV protease only little digestion was observed. As expected, cleaved Vpu remains 
without affinity tags and is precluded from binding to a talon metal affinity resin when the 
preparation is applied to a second affinity chromatography column (Figure II-9). Due to 
incomplete digestion, Vpu with C- terminal histidine tag is also found in the elution. But, 
Figure II-10: Size-exclusion chromatography of the 
FT fraction from Figure II-9. 
SEC resin: Superdex 200 10/300 GL; Flow-rate: 
0.5 mL/min, Running buffer: 20 mM HEPES, 100 
mM NaCl, 0.05% βDDM. Fraction highlighted in red 
contained the majority of Vpu. 
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the amount of contaminants co-
eluting with Vpu in the flow-through 
made the purification very 
challenging. The problem was 
compounded by the fact that the 
Mistic-Vpu protein was found to be 
very unstable over time, causing 
extensive aggregation and 
degradation, and also the use of a 
large quantity of histidine-tagged 
TEV protease which saturated the 
metal affinity resin.  
Nevertheless, in an attempt 
to purify Vpu in the flow through 
fraction from Figure II-9, the sample 
was subjected to size exclusion 
chromatography (SEC) and the 
elution profile is shown in Figure 
II-10. Vpu in bDDM micelles was 
detected in fractions highlighted in 
red in Figure II-10. The bleak 
possibility of obtaining pure, working 
amounts of Vpu is evident from the 
chromatogram. The presence of multiple peaks co-eluting with each other made the task 
of purification extremely difficult. Thus, also considering the low yield of the product, as 
Figure II-11: Talon metal affinity chromatography 
purification of MBP-Vpu.  
Detergent (βDDM)-soluble fraction containing the 
MBP-Vpu fusion protein (lane 1) was loaded onto 
Talon resin pre-equilibrated with PBS500 
supplemented with 0.05% βDDM (lane2, flow 
through). Column was washed twice with PBS500 
(lane 3 and lane 4), once with PBS + 0.05% βDDM 
(lane 5) and once with PBS, 0.05% βDDM, and 
5mM Imidazole (lane 6). Elution was done with 
PBS, 0.05% βDDM, 250 mM Imidazole (lane 7). 
Protein fractions were subjected to SDS-PAGE 
followed by silver staining (A) and immunoblot 
analysis, probed with anti-Vpu (B). 
Black arrow indicates MBP-TEV-Vpu. 
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visualized in the small peak heights 
in the chromatogram, the strategy of 
expression and purification of Vpu 
with the Mistic protein was 
discarded.  
Large-scale extraction and 
purification of MBP-TEV-Vpu.  
Towards the effort to isolate 
His-tagged MBP-TEV-Vpu from the 
rest of the cellular proteins, the 
bDDM solubilized proteins from the 
non-aqueous fraction of BL21 cells 
containing pTM869, which were 
lyzed after 4 hr post-induction with 0.1 mM IPTG, was subjected to TALON metal affinity 
purification (Figure II-11). The protein eluted in a relatively pure form, but, in presence of 
a contaminant which resolved very closely on a denaturing gel. This was also observed 
by resolving the concentrated elute from metal affinity chromatography by size exclusion 
chromatography. MBP-TEV-Vpu in βDDM micelles was detected in fractions indicated by 
the area highlighted in red in Figure II-12. These fractions contained a high amount of 
contaminant which could not be separated by SEC. As with the Mistic-Vpu fusion, our goal 
was to cleave the MBP from Vpu by using TEV protease and obtain Vpu in a purified form 
with a second round of metal affinity chromatography. The longer linker produced by the 
Gateway recombination sequence was predicted to facilitate efficient cleavage.   
Cleaved Vpu should remain without the affinity tag. However extensive experimentation 
with different incubation conditions did not yield appreciable digest. For example, the 
Figure II-12: Size-exclusion chromatography of 
concentrated metal-affinity chromatography eluate 
from Figure II-11. 
SEC resin: Superdex 200 10/300 GL; Flow-rate: 
0.5 mL/min, Running buffer: PBS, 5% glycerol and 
0.05% βDDM. Fraction highlighted in red contained 
the majority of MBP-TEV-Vpu. 
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protease seemed to have no effect 
on the fusion protein irrespective of 
the temperature and the incubation 
times (Figure II-13).  
Large-scale extraction and 
purification of MBP-PPCS-Vpu.  
The recurring challenges that 
were faced by the strategy of 
expression and purification of Vpu in 
fusion with other soluble proteins 
has been the fact that the fusion 
proteins were difficult to purify to a 
satisfactory level and were also 
difficult to cleave by in vitro protease 
digestion. Both of the fusion proteins 
so far were also unusable for 
crystallization as they stand because 
of the fact that crystallization trials 
with Mistic have so far been 
unsuccessful and MBP-TEV-Vpu 
contains a very unfavorable linker 
towards any structural studies. Hence, I experimented with a shorter cleavable linker 
between MBP and Vpu, which not only could be utilized to get rid of the fusion partner but 
also, would provide the option of proceeding with the whole fusion. Metal affinity 
purification was again utilized as the first method to separate the protein of interest from 
Figure II-13: Proteolytic cleavage of MBP-TEV-Vpu. 
MBP-TEV-Vpu fusion protein is resistant to site-
directed digestion with the TEV protease. 
Concentrated eluate (Lane 1) from the talon affinity 
chromatography step was incubated at 4 ºC (Lanes 
2-5) and 25 ºC (Lanes 6-9) for 1 hr (Lanes 2,6), 2 
hr (Lanes 3,7), 3 hr (Lanes 4,8) and ON (Lanes 
5,9). Protein samples were subjected to SDS-
PAGE followed by silver staining (A) and 
immunoblot analysis, probed with anti-Vpu (B). The 
uncleaved fusion if denoted by a black arrow. 
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other cellular impurities. MBP-PPCS-
Vpu was found to co-elute with 
another protein, which was similar in 
size as per SDS-PAGE followed by 
silver staining (Figure II-14). This 
impurity could not be eluted prior to 
the high imidazole (300 mM) wash 
by varying the ionic strengths of the 
buffer and did not react with 
antibodies against Vpu. When a 
concentrated eluate of the metal 
affinity purification was resolved on a 
size exclusion column, the 
chromatogram was found to be 
somewhat similar as in MBP-TEV-Vpu 
(Figure II-15).  
This construct was designed 
with a cleavable PreScission 
protease site. Unlike the case of 
digestion with TEV protease, 
analytical amounts of MBP-PPCS-Vpu 
could be cleaved to obtain Vpu 
without any purification and fusion 
tags. Complete digestion was only 
obtained when the fusion protein 
Figure II-14: Talon metal affinity chromatography 
purification of MBP-PPCS-Vpu.  
Detergent (βDDM)-soluble fraction containing 
MBP-PPCS-Vpu (Lane 1) was loaded onto a column 
containing Talon resin that was pre-equilibrated 
with 20 mM HEPES, pH 7.5, supplemented with 
500 mM NaCl, 5 mM imidazole, and 0.02% βDDM. 
Unbound proteins in the flow through were 
collected (Lane 2) and the column was washed 
consecutively with four different buffer solutions (20 
mM HEPES, pH 7.5): W1 (Lane 3, buffer plus 500 
mM NaCl), W2 (Lane 4, buffer plus 500 mM NaCl 
and 0.02% βDDM), W3 (Lane 5, buffer plus 250 
mM NaCl and 0.02% βDDM), and W4 (Lane 6, 
buffer plus 250 mM NaCl, 0.02% βDDM and 10 mM 
imidazole). Pure Vpu (Lane 7) was eluted with W4 
buffer supplemented with 300 mM imidazole. 
Protein fractions were subjected to SDS-PAGE 
followed by silver staining (A) and immublot 
analysis, probed with anti-Vpu (B). Black arrow 
indicates MBP-PPCS-Vpu. 
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was incubated overnight at 25 ºC 
with high amounts of protease 
(Figure II-16). This protocol turned 
out to be non-replicable when scaled 
up to the amounts of fusion protein 
obtained from 4L bacterial cultures. 
The fusion protein, in a concentrated 
form, was found to be unstable at 25 
ºC and formed insoluble 
precipitates. The consistent trend of 
Vpu being resistant to protease 
digestion could reflect a scenario 
where the protease cleavage site is 
inaccessible to the protease due to the bulky detergent micelles. Apart from the size, the 
charge characteristics of the detergent micelles could also play a role in the significantly 
reduced affinity of the proteases performing site-specific cleavage.  
Moving away from the strategy of separating the fusion partner from Vpu, I decided 
to subject MBP-PPCS-Vpu to a second round of affinity purification, utilizing the affinity of 
MBP to bind to amylose (di Guana, Lib, 1988, Maina, Riggs, 1988, Riggs, 2001). A 
substantial loss of binding was observed when I detected the protein in flow-through and 
washes (Figure II-17). Although this purification strategy has been relatively successful, 
there have been previous instances on the challenges encountered  in this process by the 
lack of substantial binding between MBP and amylose (Lo-Man et al. , 1993, Rhyum et al. 
Figure II-15: Size-exclusion chromatography of 
concentrated metal-affinity chromatography-
purified MBP-PPCS-Vpu.  
Eluate from the metal affinity chromatography 
purification was subjected to SEC-FPLC. Sec resin: 
Superdex 200 10/300 GL; Flow-rate: 0.5 mL/min, 
Running buffer: 20 mM HEPES, pH 7.5, 250 mM 
NaCl, 5% glycerol and 0.02% βDDM. The presence 
of MBP-PPCS-Vpu was detected in the two highest 
peaks contained within 10-14 mL column volume. 
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, 1994). The binding of the MBP to amylose is strictly dependent on the correct biological 
activity and thus, proper folding of the MBP. Structural disturbances of the fusion partner, 
Vpu, in the present case, can also compromise the biologically active folding of MBP with 
respect to its amylose binding affinity (Park et al. , 1998). Interestingly, the doublet of 
bands was also observed when the protein bound to the amylose resin was eluted with 10 
Figure II-16: Small scale digestion of 
MBP-PPCS-Vpu with PreScission 
protease. 
Size exclusion fractions containing 
MBP-PPCS-Vpu (lane 1) was was 
incubated at 4 ºC (Lanes 2-5) and 25 
ºC (Lanes 6-9) for 1 hr (Lanes 2,6), 2 
hr (Lanes 3,7), 4 hr (Lanes 4,8) and 
ON (Lanes 5,9). Protein samples 
were subjected to SDS-PAGE 
followed by silver staining (A) and 
immunoblot analysis with antibodies 
against the poly-histidine tag (B) and 
Vpu (C). Complete digestion was 
only achieved when MBP-PPCS-Vpu 
was incubated with molar excess of 
protease (indicated on A with a blue 
arrow) at 25 ºC. Undigested MBP is 
indicated by a black arrow and 
cleaved Vpu is indicated by a red 
arrow. 
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mM maltose, thereby hampering the 
prospects of this protein to 
crystallize successfully. 
Characterization of the concentrated 
version of this elution by dynamic 
light scattering confirmed the 
presence of multiple species in 
solution, as evident from the lack of 
a narrow red beam on the heat map 
image (Figure II-18). 
Conclusions 
The strategy of expression of 
Vpu in fusion with proteins like the B. 
subtilis Mistic and the E. coli maltose 
binding protein (MBP) were 
successful in producing decent amounts of recombinant fusion protein. Even though 
relatively pure forms of protein were obtained after the first rounds of purification, the 
stability of the fusion proteins, especially the Mistic-Vpu fusion, was found to be very poor. 
The down-stream, polishing-step purification techniques such as size exclusion 
chromatography did not go a long way in improving the sample quality. The problem was 
further compounded by the fact that all of the cleavable fusion protein were resistant 
towards proteolytic digestion, especially in preparatory scales. I hypothesize that this could 
be due to the short extra-membrane N-terminus of the protein. In this case, the bulky 
detergent molecules would obscure the cleavage site and combined with the charge 
characteristics of the detergent, could play a role in substancially reducing the activity of 
Figure II-17: Amylose column purification of MBP-
PPCS-Vpu.   
Elution from Figure II-14 (lane 1) was passed 
through an amylose column prequilibrated with 20 
mM HEPES pH 7.5, 250 mM NaCl, 0.5 mM EDTA 
and 0.02% bDDM. Unbound proteins were 
collected (lane 2) and the column was washed with 
10 column volumes of the equilibration buffer (lane 
3) and elution was done by supplementing the 
wash buffer with 10 mM maltose (lane 4). Protein 
samples were subjected to SDS-PAGE followed by 
silver staining (A) and immunoblot analysis (B). 
MBP-PPCS-Vpu is indicated with a black arrow. 
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the protease. To this regard, further 
proteolytic digestion experiments 
with the proteins in smaller detergent 
micelles could be a future prospect.  
Hence, towards our goal of 
exploring various strategies of 
expression of Vpu for crystallization, 
I conclude that the expression of 
Vpu in fusion with other helper 
proteins provides for samples that 
are not amiable for the rigorous 
standards required for structural 
studies and thus, other innovative 
strategies should be explored. 
  
Figure II-18: Dynamic light scattering analysis of 
MBP-PPCS-Vpu. 
Amylose affinity purified MBP-PPCS-Vpu was 
concentrated to 10 mg/mL and was analyzed for 
dispersity. The sample was polydisperse as shown 
in the above heat map. 
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III. Expression, purification and characterization of HIV-1 Viral protein U using 
PelB signal peptide. 
Abstract 
Viral protein U (Vpu) is a type-III integral membrane protein encoded by Human 
Immunodeficiency Virus-1 (HIV- 1). It is expressed in infected host cells and plays several 
roles in viral progeny escape from infected cells, including down-regulation of CD4 
receptors. But key structure/function questions remain regarding the mechanisms by 
which the Vpu protein contributes to HIV-1 pathogenesis. Here I describe expression of 
Vpu in bacteria, its purification and characterization. I report successful expression of Vpu 
in the Escherichia coli using the leader peptide pectate lyase B (PelB) of Erwinia 
carotovora. The protein was detergent extractable and could be isolated in a very pure 
form. I demonstrate that the PelB signal peptide successfully targets Vpu to the cell 
membranes and inserts it as a type I membrane protein. Vpu was biophysically 
characterized by circular dichroism and dynamic light scattering experiments and was 
shown to be an excellent candidate for elucidating structural models. 
Introduction 
Structural analysis of membrane proteins has traditionally been bottlenecked by 
the lack of sufficiently large amounts of pure, properly folded and functional membrane 
proteins. The issue is particular important considering the fact that membrane proteins 
constitute a significant proportion of clinical drug targets.  
The Viral protein U (Vpu) was identified as product of the vpu open reading frame 
from the Human Immunodeficiency Virus-1 (HIV-1) which runs as a 16 kDa protein on a 
SDS-polyacrylamide gel (Strebel, Klimkait, 1988a). It is a type III trans-membrane protein 
77-86 amino acids in length depending on the group and subtype of HIV-1.  Vpu is not 
expressed by HIV-2 but is present in some simian immunodeficiency viruses (SIVs) 
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(Cohen et al. , 1988a). It has a very short N-terminal domain; a trans-membrane domain 
and a longer cytoplasmic domain, which has two predicted α-helical domains, separated 
by a hinge region. The hinge region contains two potential casein kinase II sites (Schubert, 
Schneider, 1992b). NMR characterization of the cytoplasmic domain of Vpu indicates that 
there is a great deal of structural flexibility in the cytoplasmic domain (Wittlich, Koenig, 
2009a). 
Down-regulation of CD4 receptors in the infected host cells is of prime importance 
for the virus and it accomplishes this through the Nef and Vpu proteins. Vpu not only 
retains CD4 in the endoplasmic reticulum but also induces CD4 degradation by employing 
a variant pathway of the ERAD machinery (Magadán et al. , 2010). Vpu retains CD4 in the 
ER by virtue of their interactions at the trans-membrane domain. The conserved 
tryptophan residue (Trp22 in NL4-3 strain Vpu sequence) in the trans-membrane domain 
of Vpu plays a role in inhibiting the dislocation of the CD4 from ER membrane to the 
cytosol for degradation. Val20 and Ser23 have also been identified to play a role in CD4 
retention in the ER (Magadán and Bonifacino, 2012). The cytosolic domain of Vpu recruits 
the ubiquitination factors which ubiquitinate the cytoplasmic domain of CD4 at multiple 
lysine and serine/threonine residues to mark CD4 for proteasomal degradation and also 
further contribute in retention of CD4 in the ER (Magadán, Pérez-Victoria, 2010).  
The trans-membrane domain of Vpu is involved in its association with tetherin. This 
lead to reduced levels of tetherin at the plasma membrane of the cells and thereby 
prevents the incorporation of tetherin into nascent virions. Tetherin is then degraded by 
an ubiquitin dependent mechanism in which phosphorylated Vpu recruits a SCG TRCP1/2 
E3 ligase complex to ubiquitinate the cytoplasmic tail of tetherin at multiple residues. A 
motif in the second α-helix in the cytoplasmic domain of Vpu has been identified 
responsible for efficient counteraction of tetherin has been found (Kueck and Neil, 2012b).  
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Vpu has also been implicated in retention of NK, T-cell, B-cell antigen (NTB-A) in 
the Golgi apparatus by altering the glycosylation pattern in nascent NTM-A. This is a part 
of a strategy to prevent HIV-1 infected cells to be lysed by NK cells. This function has been 
traced to the second α-helical region of Vpu in its cytoplasmic domain (Bolduan et al. , 
2013b). In addition, based on similarities with other viral trans-membrane proteins, Vpu 
has also been studied for possessing an ion-channel activity, which could potentially make 
the host membrane protein more permeable and aid in budding and release of nascent 
virions. Vpu has been shown to mediate potassium transport when expressed 
recombinantly in Saccharomyces cerevisiae (Herrero et al. , 2013b). 
The 22 amino acid PelB signal sequence was first described in the identification 
and characterization of Erwinia carotovora pectate lyase B gene and its protein product 
(Lei et al. , 1987). The expression of the mature form of the protein in Escherichia coli was 
indicative of the fact that E. coli contains peptidases to cleave the signal peptide in its 
periplasmic space. Since then a wide variety of recombinant soluble proteins have been 
efficiently targeted to the E. coli periplasm and also to the extracellular media using this 
signal peptide like the ligand binding domains of glutamate binding receptor B and D 
subunits (Arvola and Keinänen, 1996) variable regions of light and heavy chains of 
antibodies (Fecker et al. , 1996, Power et al. , 1992), phospholipase D (Iwasaki et al. , 
1995), and the C terminal domain of OMP C (Walsh et al. , 2003). The PelB signal peptide 
was also used to express a pentameric ion channel ELIC with a N-terminal fusion of 
maltose binding protein, which also led to the successful crystallization and x-ray structure 
determination of ELIC (Hilf and Dutzler, 2008). It was also used to targeting of a fusion of 
the B subunit of cholera toxin (CTB) and the membrane proximal region (MPR) of HIV-1 
GP41, which, interacts with the membrane on the periplasmic side of the E. coli cells (Lee 
et al. , 2014, Matoba et al. , 2008, Matoba et al. , 2004).  
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In this study I report the successful expression of a eukaryotic type III membrane 
protein, Vpu, in E. coli by expressing it as a type I membrane protein in the presence of 
the PelB signal sequence. I also describe the purification and characterization of the target 
protein towards its suitability for structure determination by X-ray crystallography. 
Materials and Methods 
Target selection, gene optimization and cloning. 
The sequence of HIV- 1 group M subtype B strain HXB2 Vpu was used. 
Unfavorable codons for each 82 amino acids in length were replaced using the E. coli 
codon usage table (Sharp and Li, 1987). The vpu gene optimized for expression in E. coli 
was synthesized as described in Chapter II. The vpu gene was sub-cloned into a TOPO-
TA vector with flanking NcoI and BlpI sites and a C-terminus hexa- histidine tag using 
oTMs 787 and 788 (Table III-1) and was excised from this intermediate vector by digestion 
with NcoI (NEB; cat# R3193S) and BlpI restriction enzymes (NEB; cat# R0585S). The 
same pair of restriction enzymes were also used to linearize the pET26(b) vector by 
Novagen.  
Table III-1: DNA primers used towards the creation of pTM875 
Primer Sequence (5’ à 3’) 
oTM 662 atgcagccgatcccgatcg 
oTM 663 cagatcgtcaacgtcccacgg 
oTM 787 ccatgggcatgcagccgatcccgatcgttgc 
oTM 788 gctcagcttaatggtgatggtgatggtgcagatcgtcaacgtcccacggagcg 
oTM 856 atgaaatacctgctgccgaccgctgc 
oTM 857 cccattcgccaatccggatatagttcctcc 
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The restriction digestion reactions were analyzed by agarose gel electrophoresis 
and the desired DNA bands were excised and purified using a QIAquick gel extraction kit 
(Qiagen; cat# 28704). The gene was ligated to the pET26(b) vector by performing a T4 
DNA ligase reaction (Promega; cat# M1801) and transformed into DH5α electro-
competent cells. The resulting bacterial colonies were screened using colony screen PCR 
using gene specific primers oTMs 662 and 663 and plasmid specific primers, oTMs 856 
and 857. DNA sequencing using oTMs 856 and 857 was used to verify the final expression 
clone, pTM875.  
Expression 
The expression of Vpu with the N terminal PelB signal peptide, along with the C 
terminal metal affinity tag was driven by a T7 promoter. E. coli BL21 DE cells were 
transformed with the expression vector, pTM875 by electroporation. For protein 
expression, an overnight culture of BL21 DE cells containing the expression vector was 
grown in LB media supplemented with 100 μg/mL kanamycin (Phytotechnology lab; cat# 
K378) and was used to inoculate a fresh LB media with 50 μg/mL kanamycin in a 1:100 
dilution. The cultures for expression were shaken at 200 rpm at 37 ºC to mid-logarithmic 
phase (OD600 ≈ 0.4). The cultures were then moved to 15 ºC and incubated for additional 
30 min with 200 rpm shaking. Finally, the cultures were induced for expression with 0.1 
mM Isopropyl-β-D-thiogalactoside (IPTG, Roche; cat# 11411446001). For standardization 
of expression conditions, 5 mL of culture were collected at various time points after IPTG 
induction and pelleted by centrifugation at 5000 ×g, 4 ºC for 15 min. For detergent 
extraction screens and subsequent purifications, cells were harvested at 6 h post induction 
by centrifugation at 5000 ×g, 4 ºC for 15 min. Cell pellets were stored at -80 ºC until further 
use. 
Separation of water-soluble and insoluble fractions 
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Cell pellets from 4 L worth of culture (approximately 12 g) were re-suspended in 
100 mL of ice-cold PBS-PI buffer (phosphate buffer saline, PBS, supplemented with 
EDTA-Free SIGMAFAST™ Protease Inhibitor Cocktail tablets, Sigma; cat# S8830). The 
cells were lysed by double passage through a microfluidizer (Microfluidics Microfluidizer). 
The lysate was collected and centrifuged at 36,000 ×g for 30 min at 4 ºC. The insoluble 
fraction, containing the inner and outer membranes among other insoluble materials like 
protein inclusion bodies, was washed once by repeated re-suspension (50 mL of ice-cold 
PBS with protease inhibitor cocktail) and centrifugation. The pellet was frozen at -80 ºC 
until further use. 
Detergent extraction 
Aqueous and non-aqueous fractions from 500 mL cultures were prepared as 
described above, induced for expression and cells were harvested as pellets as mentioned 
previously. The pellet containing the non-aqueous proteins was re-suspended in 25 mL of 
PBS-PI buffer. Samples (4 mL) were then subjected to detergent extraction by addition of 
the following detergents to final concentration of 1% (w/v): n-dodecyl-β-D-maltoside 
(βDDM, Glycon Biotech; cat# D97002C), n-decyl-β-D-maltoside (βDM, Anatrace; cat# 
D322), 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS, Mclab; 
cat# DCPS101), n-octyl β-D-glucopyranoside (OG, Glycon Biotech; cat# D97001C), n-
dodecylphosphocholine (DPC, Anatrace; cat# F308S) and n-dodecyl-N,N-dimethylamine-
N-oxide (LDAO, Anatrace; cat# D360). The samples were left overnight at 4 ºC with 
agitation at 200 rpm and centrifuged at 36,000 ×g for 30 min at 4 ºC on the following day 
and the supernatant was collected as the detergent soluble fraction. The fractions were 
analyzed by SDS-PAGE followed by Coomassie staining and western blot. 
For large-scale extractions from 4 L cultures, the pellet, containing the membrane 
fraction, was fully re-suspended in 200 mL PBS supplemented with EDTA-Free 
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SIGMAFAST™ Protease Inhibitor Cocktail tablets. βDDM was used for solubilization at a 
final concentration of 1% (w/v). The protein was extracted and at 4 ºC overnight with 
agitation at 200 rpm. The detergent soluble fraction was obtained by collecting the 
supernatant after centrifugation at 36,000 ×g for 30 min at 4 ºC. 
Purification 
A gravity driven column (Biorad Econo-column) containing 60 mL bed volume of 
TALON metal affinity resin (Clontech laboratories Ltd; Cat# 635503) was equilibrated with 
binding buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 0.02% βDDM, 5 mM imidazole). 
The sample was then loaded onto the column, and passed twice. The column was washed 
with ten bed volumes of wash buffers containing various combinations of salt and 
imidazole, for example, 20 mM HEPES, pH 7.5 with 500 mM NaCl (Wash I), 500 mM NaCl, 
0.02% βDDM (Wash II), 250 mM NaCl, 0.02% βDDM (Wash III) and 250 mM NaCl, 0.02% 
βDDM, 5% glycerol, 10 mM imidazole (Wash IV) to remove weakly bound proteins. Tightly 
bound proteins were eluted by application of 3 bed volumes of elution buffer (20mM 
HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, 5% glycerol, 300 mM imidazole). 
The eluted sample was concentrated by 100 kDa molecular weight cutoff (MWCO) 
concentrators (Millipore; cat# UFC910024) to approximately 1/20th its original volume. 
Concentrated samples were further purified by size exclusion chromatography (GE Life 
sciences, Superdex 200 10/300 GL; column volume: 24 mL; fluid phase: 8 mL) using a 
fast pressure liquid chromatography instrument (FPLC, Pharmacia, Äkta Explorer). The 
running buffer contained 20 mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, and 5% 
glycerol. For preparatory separations, a 1 mL sample of concentrated Vpu was loaded 
onto the SEC column and chromatography was performed at a flow rate of 0.5 mL/min. 
The protein elution was detected by absorption at 280 nm. The concentration of protein in 
the desired peak was determined spectrophotometrically (A280) based on the primary 
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sequence of Vpu; Σ280 was calculated with ProtParam web application 
(http://web.expasy.org/protparam/).  
Determination of Vpu orientation in the E. coli inner membranes 
A 500 mL LB media, supplemented with 50 μg/mL kanamycin, was inoculated with 
an overnight culture of BL21 – pTM875 at a dilution of 1:100. The culture was grown and 
induced with 0.1 mM IPTG as mentioned above. The culture was allowed to shake at 180 
RPM for 3 hr at 15 ºC post-induction after which the cells were harvested by centrifugation 
at 5000 ×g for 15 min at 4 ºC. The cells were gently and thoroughly re-suspended in 10 
mL of 200 mM TRIS, 500 mM sucrose and 0.1 mM EDTA and were distributed into 1 mL 
aliquots. Lysozyme was added at a final concentration of 2 mg/mL and mixed 3 times with 
gentle inversion and incubated on ice for 20 min. Calcium chloride was added at a final 
concentration of 30 mM and chymotrypsin at 1:1000, 1:100 and 1:50 v/v ratio was added 
to the appropriate tubes from a stock of 1 mg/mL. Triton X-100 was added at a final 
concentration of 2% for controls performed with fully lysed cells. The digestion was done 
at 25 ºC for 1 hr, with gentle mixing every 15 min. Finally, the cells were lysed by the 
addition of SDS sample buffer and heating at 100 ºC before analyzing the results by SDS 
gel electrophoresis followed by immuno blot and coomassie staining.   
Co-immunoprecipitation with CD4 
A deconstructed version of human CD4 containing the transmembrane and the 
cytoplasmic domains with an N- terminal fusion of maltose binding protein was expressed 
in BL21 cells. The protein was extracted and solubilized in buffer containing 0.02% βDDM 
and purified by metal affinity followed by size exclusion chromatography. MBP was 
expressed with an N-terminal histidine tag in BL21 strain of E. coli cells and similarly 
purified by metal affinity and size exclusion chromatography. 25 μM of the MBP-CD4 
fusion was incubated with 50 μM Vpu for 45 min at 4 ºC. The reaction was incubated with 
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antibodies against MBP at a dilution of 1:200 for 1 hr followed by 20 μL of Protein A/G 
PLUS- Agarose immunoprecipitation reagent (Santa Cruz Biotechnology; cat # sc-2003) 
overnight at 4 ºC. The agarose beads were pelleted by centrifugation at 500 ×g for 5 min 
at 4 ºC. The beads were washed 4 times with 1 mL of 20 mM HEPES pH 7.5, 250 mM 
NaCl, 0.02% βDDM and centrifuged for 500 ×g for 5 min at 4 ºC. Finally, the beads were 
resuspended in 1× SDS sample buffer and were analyzed by SDS-PAGE followed by 
immuno-blot analysis using antibodies against Vpu.  
Gel electrophoresis, staining and western blots 
SDS-PAGE using TRIS - based buffers (25 mM TRIS, 200 mM glycine and 3.5 mM 
SDS) was performed in a Biorad Mini-PROTEAN Tetra Cell. Following electrophoresis, 
gels were stained by coomassie brilliant blue, subjected to silver staining, or processed 
for immuno-blotting. For immuno-blotting, the acrylamide gel was first rinsed with water 
and equilibrated in a non-denaturing buffer (25 mM TRIS base and 200 mM glycine). The 
nitrocellulose membrane (Biorad; cat# 162-0112) was also equilibrated in the non-
denaturing buffer. The gel and the membrane were sandwiched between extra-thick blot 
filter papers (VWR; cat# 28298-014) soaked in the non-denaturing buffer and proteins 
were electro- blotted for 15 min at 15 V using a Biorad Transfer-blot SD Semi-Dry Transfer 
Cell. Following an hour long blocking in PBSTM (PBS, 0.05% Tween 20 and 5% dry milk), 
the nitrocellulose membrane was further incubated in the presence of the appropriate 
primary antibody. The membrane was then washed 3×15 min in PBST (PBS and 0.05% 
Tween 20) prior to a one-hr incubation with the appropriate secondary antibody 
conjugated to horseradish peroxidase. Following additional 3× 15 min washes, the 
nitrocellulose membrane was then soaked in Immunocruz western blotting luminol reagent 
(Santa Cruz Biotechnology; cat# sc-2048), exposed to a chemiluminescence sensitive film 
(GE Heathcare; cat# 28906838) for the optimum time of exposure and the film was 
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developed with a Konica SRX-101A system. Anti- Vpu polyclonal antibody, raised in 
rabbits, was kindly provided by the NIH’s AIDS Reagent Program and was used at a 
dilution of 1: 30,000. Antibodies against AcrA and GroEL, raised in rabbits, were kind gifts 
from the lab of Professor Rajeev Misra. Goat anti-rabbit IgG - HRP (Santa Cruz 
Biotechnology; cat# sc-2923) and rabbit anti-mouse IgG-HRP (Sigma A-9044) were used 
at a dilution of 1: 10,000 in PBSTM. 
Mass spectrometry 
I used matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) Mass 
spectrometry (MS) to accurately measure the molecular weight of the purified Vpu protein. 
Purified Vpu (1 μL of 10 mg/mL) was added to 4 μL of sinapinic acid matrix solution (67:33 
water:acetonitrile (v/v) containing 0.4% trifluoroacetic acid in the total volume, saturated 
with sinapinic acid). The protein/ matrix mixture (1 µL) was added onto a steel target plate 
and allowed to dry in air. An external calibration spot prepared in a similar manner was 
placed near the Vpu protein spot.  The plate was then placed into a Bruker microflex 
MALDI-TOF mass spectrometer, and spectra were collected in a positive linear mode over 
a mass range from 1 to 30 kDa. The final results represented the average of 10 separate 
spectra.  
Circular dichroism.  
A JASCO J-710 CD spectro-polarimeter was used for measuring the Circular 
dichroism (CD) spectra of the purified sample at various salt and temperature conditions. 
The SEC-purified Vpu (eluted in 20 mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, and 
5% glycerol) was concentrated to 10 mg/mL by a 100-kDa concentrator and CD 
measurement was done on samples containing a final protein concentration of 0.5 mg/mL. 
A baseline CD spectrum was obtained for the buffer and these values were subtracted 
from the CD measurement of Vpu. CD spectra for the protein were recorded from 190 to 
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260 nm using a 0.1 cm quartz cuvette. To obtain readings for the protein at different salt 
concentrations, a temperature of 20 °C was maintained throughout. Parameters were set 
at 1 nm data pitch, continuous scanning mode, a scanning speed of 50 nm/min, a 
response of 4 s, and a spectral bandwidth of 1 nm. Output spectra were generated based 
on an accumulation of five scans. The molar ellipticity (θ) in deg.·cm2/dmol was calculated 
as described by (Greenfield, 2006).  
Dynamic light scattering 
Dynamic light-scattering (DLS) measurements were performed using a NaBiTec 
GmbH setup comprising a SpectroSize 302 (Molecular Dimensions) in combination with 
an S6D microscope (Leica). The purified protein sample was concentrated to 10 mg/mL 
as described earlier was illuminated in a 2 μL hanging drop using a 24-well crystallization 
plate (VDX Greased Plate, Hampton Research) covered with siliconized-glass circular 
cover slides (22 mm; Hampton Research). The well itself was filled with 400 μL SEC 
running buffer. Prior to the measurement, the protein solution was centrifuged at 18000 
×g, 30 min, 4oC to remove possible dust and other suspended particles. All measurements 
were done at 20 ºC. Ten consecutive measurements, each with an integration time of 20 
s, were averaged. Hydrodynamic size of the particles was estimated with the instrument 
software using the following parameters: refractive index 1.33, viscosity 1.006, shape 
factor 1.0 and hydrated shell 0.2 nm. 
Results and Discussion. 
Gene Optimization, Cloning and Expression of Vpu. 
Vpu is an important accessory protein involved in HIV-1 pathogenesis. 
Furthermore, the presence of a transmembrane domain with an intriguing structure-
function relationship makes it an attractive target for structural studies. Previous attempts 
to express this protein were either unsuccessful, as with P8CBD expression vector 
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described in Luo, Choulet (2009) 
and in Chapter II , or resulted in 
proteins with unsatisfactory purity 
and stability to pursue them further 
for crystallization as was observed 
with an expression construct with a 
N-terminal fusion of Bacillus subtilis 
protein Mistic (see Kefala et al. , 
2007, Chapter II). In this study, 
unfavorable codons from the native 
Vpu gene from subtype B HIV-1 
were removed and were replaced by 
codons widely used in the E. coli 
expression system (Figure II-5). This 
E. coli optimized gene was cloned into the expression vector to obtain pTM875 (Figure 
III-1) with the addition of a C-terminal hexameric histidine tag.  
Bacterial cells harboring pTM875 were grown to mid-logarithmic phase when 0.1 
mM IPTG was added to the culture medium to induce expression of the recombinant Vpu. 
At 6 h post induction, cells were harvested and lyzed by a microfluidizer. Following cell 
lysis, cellular components were fractionated into aqueous and non-aqueous fractions and 
their proteins resolved by SDS-PAGE. Immunoblot analysis revealed the almost-exclusive 
presence of Vpu in the water-insoluble fraction. However, Vpu could be extracted from the 
water-insoluble fraction with detergents. Particularly effective in extraction of Vpu were the 
maltoside detergents βDM and βDDM and the zwitterionic detergent, DPC (Figure III-2). 
These three detergents have relatively long and flexible hydrophobic chains, which may 
Figure III-1: Organization of the expression 
cassette on pTM875.  
Expression was driven by a T7 promoter as shown 
in (A). The Vpu gene is flanked by the pelB signal 
peptide at the N-terminus which, directs the protein 
to the periplasmic space of the bacteria and thereby 
helping it integrate into the inner membranes, and 
a 6x- histidine tag at the C- terminus to aid in 
purification. (B) shows the sequence of the pelB 
signal peptide (in orange), Vpu (in green) and 
histidine tag (in blue). Chymotrypsin cleavage sites 
are denoted by ( ) for strong catalytic sites and by 
(*) for secondary catalytic sites. 
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be necessary for the ability of these 
detergents to effectively extract the 
highly hydrophobic Vpu protein. 
Accordingly, the shorter-chained OG 
and CHAPS, whose hydrophobic tail 
consists of a rigid steroidal ring 
system, have relatively ineffective 
extraction power. Long flexible 
hydrophobic tails may be necessary 
for successful extraction of Vpu, but 
apparently are not sufficient as 
LDAO performed poorly: its 
solubilization power may be 
hampered by a very small 
hydrophilic head (18 .2 as compared 
to 59 .2 and 179 .2 of DPC and the two maltoside detergents, respectively) (National 
Center for Biotechnology Information, 2016a, b, c) and a high octanol/water partition 
coefficient (logP > 5.3) (National Center for Biotechnology Information, 2016a). Based on 
its performance and its suitability for downstream applications, I elected to use βDDM in 
all subsequent experiments. 
Vpu is targeted to the membranes and inserted as a type I membrane protein. 
In mammalian cells, the Vpu transmembrane domain serves as a signal-anchor to 
target the protein for insertion into the membrane, but when expressed in bacteria, the 
domain cannot support this targeting function, resulting in the accumulation and 
aggregation of the protein in inclusion bodies (Ma et al. , 2002). The PelB leader sequence 
Figure III-2: Vpu fractionates with the water 
insoluble fraction and can be subsequently 
solubilized by detergents.  
Whole cell lysates of BL21 strains of E. coli were 
fractionated into non- aqueous (lane 1) and 
aqueous (lane 2) fractions by centrifugation. The 
non-aqueous fraction (pellets) were resuspended 
in extraction buffer containing various detergents 
(1% final concentration): βDM (lane 3), βDDM (lane 
4), CHAPS (lane 5), OG (lane 6), LDAO (lane 7) 
and DPC (lane 8). Following overnight incubation 
at 4 ºC, Detergent-soluble proteins were separated 
from detergent-insoluble proteins by centrifugation 
and fractionated by SDS-PAGE followed by 
immunoblot analysis. Vpu is indicated by a black 
arrow. 
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targets its cargo protein pectate lyase B of Erwinia carotovora into the periplasm via the 
Sec-dependent pathway (Berks et al. , 2000, Steiner et al. , 2006, Thie et al. , 2008), which 
is also used for targeting integralmembrane proteins to the inner membrane (Hartl et al. , 
1990). While PelB is commonly used to direct recombinant proteins to the periplasm of 
Gram-negative bacteria, there are not many examples of its application in targeting 
membrane proteins to the bacterial inner membrane as was intended here. Because the 
non-aqueous fraction obtained after cell lysis contain both membranes with their 
respective membrane proteins and aggregated proteins in the form of inclusion bodies, 
the question arose as to the partition of the recombinant Vpu between these two 
compartments.  
To answer this question, I used differential extraction of Vpu from samples of 
water-insoluble protein fractions obtained at various times after the beginning of 
recombinant protein induction. To this end, I used the mild detergent of choice, βDDM, to 
extract membrane proteins and subjected the residual detergent-insoluble proteins to 
extraction with 8 M Urea, a chaotropic agent that can solubilize protein inclusion bodies 
(Alexander et al. , 1992, Kuhelj et al. , 1995, Patra et al. , 2000). Extractions were carried 
out at the specified time points following the induction with IPTG. The amount of Vpu 
extractable with βDDM increased with time during the first 6 hr post-induction (Figure 
III-3A). However, there was only a slight increase of the Vpu amount that could be 
extracted from homogenization pellets of cells harvested after overnight growth in the 
presence of IPTG as compared to 6 hr. In striking contrast, the overnight sample had a 
significant increase in amount of urea-extractable Vpu between the same time points. This 
could be explained by saturation of the bacterial inner membrane by 6 hr post induction 
and subsequent accumulation of the over-expressed protein in intracellular inclusion 
bodies. Urea cannot extract integral membrane proteins embedded in membranes, but 
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such proteins can be extracted by 
detergents. Conversely, detergent-
extractable proteins may be present 
in inclusion bodies, but such proteins 
should also be solubilized by urea. 
To rule out this second possibility, 
and to further demonstrate that 
βDDM predominantly extracts Vpu 
from the cell membranes rather than 
from inclusion bodies, I reversed the 
order of extraction such that the non-
aqueous fraction was first subjected 
to urea extraction followed by βDDM 
extraction. Most of the protein from 
cells harvested 2 h and 4 h after 
induction was in the βDDM 
extractable fraction (Figure III-3B). 
This indicates that most of the 
protein localizes in the membrane 
fraction until around 6 h after 
induction with IPTG, after which the 
membranes may saturate and the subsequently produced recombinant protein forms 
aggregates that can be solubilized by urea. Based on this finding, the cells were harvested 
after 6 hr of IPTG induction for all subsequent experiments. 
Figure III-3: Fractionation of Vpu between 
membranes and inclusion bodies. 
Vpu fractionates between membrane fraction and 
inclusion bodies depending on time post- induction 
with IPTG. The βDDM extractable fraction 
increases with time until it reaches saturation 
around 6 hr (A). When the non–aqueous fraction is 
first treated with urea and then βDDM (B), the 
protein first fractionates in the detergent fraction, 
implying that protein does integrate in the 
membranes that is extractable by βDDM. Vpu is 
indicated by a black arrow. 
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The PelB sequence allows the insertion of recombinant Vpu into the membrane, 
however the presence of two in tandem hydrophobic domains may complicates the 
membrane topology of the protein. To settle this question, I next sought to determine in 
Figure III-4: Vpu is inserted into the 
bacterial inner membrane with its C-
terminal domain within the 
cytoplasm. 
Panel A depicts the possible 
outcomes when E. coli cells (I) and 
protoplasts (II III and IV) that express 
Vpu are challenged with 
chymotrypsin (I-IV) and Triton X-100 
(IV). If the C-terminal domain of Vpu 
is protected by the inner membrane 
(I and II), it is expected to be resistant 
to chymotrypsin digestion, similar to 
the case of the cytoplasmic resident 
protein GroEL. If the C-terminal 
domain of Vpu is exposed at the 
periplasmic space of the cells (III), it 
is expected to be digested in the 
same way as AcrA. All three proteins 
should undergo chymotrypsin 
cleavage when the inner membranes 
are compromised by the addition of 
Triton X-100 (IV). E. coli cells (lanes 
1 and 3) and protoplasts (lanes 2 and 
4-8) were incubated without 
chymotrypsin (lanes 1, 2, and 7) or 
with the indicated concentrations of 
chymotrypsin (μg/mL); in the 
presence of 1% Triton X-100 (lanes 
7 and 8) or its absence (lanes 1-6). 
Following treatments, cells were 
lysed in the presence of SDS sample 
buffer and protein samples were 
resolved by SDS-PAGE followed by 
immunoblotting. Detecting Abs were 
against the periplasmic domain of the 
inner-membrane protein AcrA (Panel 
B, indicated by a red arrow), against 
the cytoplasmic protein GroEL (panel 
C, indicated by a blue arrow) and 
against the C-terminal domain of Vpu 
(Panel D, indicated by a black arrow). 
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vivo whether the protein is oriented 
with its N-terminus outside of the cell 
(in the periplasm, functionally 
equivalent to the ER lumen in human 
cells) and its C-terminus inside the 
cell (in the cytoplasm). To this end I 
converted E. coli cells expressing 
PelB-Vpu into protoplasts by 
lysozyme treatment. The protoplasts 
were subjected to mild chymotrypsin 
proteolysis. The C-terminal domain 
of Vpu contains several 
chymotrypsin proteolytic sites, which 
should be protected from the 
protease if the protein is inserted 
with its C-terminus in the cytoplasm. 
However, if the orientation of the 
protein is such that the C-terminus is 
externally-exposed, it will be cleaved 
and should not react with the 
polyclonal antibodies against Vpu. 
Indeed, the chymotrypsin digestion assay revealed that the C-terminal domain of Vpu is 
shielded from proteolytic digestion by the E. coli inner membrane (Figure III-4). In contrast, 
the periplasmic domain of AcrA, a native E. coli inner-membrane efflux pump, was 
vulnerable to proteolytic cleavage. (Figure III-4A). The cytoplasmic chaperone GroEL, like 
Figure III-5: Talon metal affinity chromatography 
purification of Vpu.  
Protein fractions were subjected to SDS-PAGE 
followed by silver staining (A) and immublot 
analysis. (B). Detergent (βDDM)-soluble fraction 
containing Vpu (Lane 1) was loaded onto a column 
containing Talon resin that was pre-equilibrated 
with 20 mM HEPES, pH 7.5, supplemented with 
500 mM NaCl, 5 mM imidazole, and 0.02% βDDM. 
Unbound proteins in the flow through were 
collected (Lane 2) and the column was washed 
consecutively with four different buffer solutions (20 
mM HEPES, pH 7.5): W1 (Lane 3, buffer plus 500 
mM NaCl), W2 (Lane 4, buffer plus 500 mM NaCl 
and 0.02% βDDM), W3 (Lane 5, buffer plus 250 
mM NaCl and 0.02% βDDM), and W4 (Lane 6, 
buffer plus 250 mM NaCl, 0.02% βDDM and 10 mM 
imidazole). Pure Vpu (Lane 7) was eluted with W4 
buffer supplemented with 300 mM imidazole, 
indicated by a black arrow on (A) and (B). 
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the cytoplasmic domain of Vpu, was 
immune to the effects of 
chymotrypsin (Figure III-4B and 4C 
respectively). Vpu and GroEL could 
be digested by chymotrypsin only 
when the integrity of the E. coli inner 
membranes was compromised by 
treatment with the detergent triton X-
100. The results of this experiment 
support the hypothesis that PelB-
Vpu is inserted into the membrane 
with its C-terminal domain located in 
the cytoplasm and its N-terminus 
projecting into the periplasm.  
Purification of Vpu 
Immobilized metal affinity 
purification of membrane protein- detergent complexes can be challenging in terms of 
amount and purity of the enriched protein. The choice of detergent and buffers can have 
some effect on the efficiency of the purification procedure (Loo and Clarke, 1995, Peters 
et al. , 1995). The conformation of the protein could also play a vital role towards the 
retention of the protein in the affinity resin (Janssen et al. , 1995, Lindner et al. , 1992). 
The folding state can also dictate the placement of the affinity tag in the protein and its 
accessibility to the metal resin (Waeber et al. , 1993). Towards my effort to isolate His-
tagged Vpu from the rest of the cellular biomolecules, the βDDM solubilized fraction was 
subjected to TALON metal affinity. I observe that the protein in the elution fraction was 
Figure III-6: Size-exclusion chromatography of 
concentrated metal-affinity chromatography-
purified Vpu. 
 Eluate from Figure III-5 was subjected to SEC-
FPLC. Sec resin: Superdex 200 10/300 GL; Flow-
rate: 0.5 mL/min, Running buffer: 20 mM HEPES, 
pH 7.5, 250 mM NaCl, 5% glycerol and 0.02% 
βDDM. The minor peak at 8 mL corresponded to 
void volume, and the major peak at 11.48 mL 
contained Vpu. The column was calibrated with 
cytochrome c (A), carbonic anhydrase (B), albumin 
(C), alcohol dehydrogenase (D), β-amylase (E) and 
blue dextran (F) and a standard curve was obtained 
as shown in the inset. The size of the Vpu- βDDM 
complex was estimated to be 315 kDa. 
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obtained in a highly pure form 
(Figure III-5A). I was also able to 
obtain our target protein with 
minimal loss during the purification 
procedure in the flow-through and 
wash steps (Figure III-5B). Although 
the quality of the eluate was 
demonstrated by denaturing gels, it 
is also important to analyze the 
sample for high molecular weight 
aggregates, which may be 
undetectable due to the denaturing 
and reducing nature of SDS-PAGE. With this objective, concentrated IMAC purified 
protein was analyzed by size exclusion chromatography. I observe that the protein eluted 
as mostly a solitary peak. Void volume aggregates eluted as a distinctly small distinct peak 
before the major peak, which was easily separated and discarded before proceeding onto 
further characterization procedures (Figure III-6). 
Size of Vpu 
My results so far suggest that the fusion of the PelB signal sequence converted de 
facto Vpu, a Type III membrane protein, into a protein more akin to a Type I membrane 
protein. However, unlike most Type I proteins, from which the signal peptide is typically 
cleaved concomitantly to their insertion into the membrane, the apparent molecular mass 
of the recombinant protein of approximately 17.5 kDa, as estimated from denaturing gels, 
suggests that the PelB sequence is not cleaved off Vpu. Vpu is known to align with a size 
of 16 kDa when analyzed with SDS-PAGE (Strebel, Klimkait, 1988a). The predicted 
Figure III-7: Mass spectrometry analysis of PelB-
Vpu. 
MALDI-TOF spectrum of Vpu reveals that the 
purified protein retains the PelB peptide. The major 
peak corresponding to the MH+ form of the protein 
was noticed at 12467.7 Da 
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molecular mass of Vpu based on its 
primary structure including the 
engineered poly-histidine tag and 
PelB is 12463.7 Da. If the signal 
peptide would be cleaved the 
predicted molecular mass would be 
10,064.7 Da. To precisely determine 
the size of the bacterially-produced 
human protein, I subjected the 
protein mass spectrometry (MALDI-
TOF, Figure III-7). The peak 
representing the MH+ form of the 
protein at 12467.7 Da, corresponds 
well to the scenario in which the 
PelB signal peptide remains 
uncleaved. Inefficient cleavage by 
periplasmic peptidases could be a 
result of steric hindrance due to the 
proximity of the cleavage site and 
the five residue-long N-terminal 
ectodomain to the hydrophilic heads 
of phospholipids in the outer leaflet 
the plasma membranes of E. coli. 
The size of the non-denatured Vpu 
within the context of its associated βDDM micelle is shown by size exclusion 
Figure III-8: Dynamic light scattering measurement 
of PelB-Vpu. 
DLS measurement proves that PelB-Vpu is 
monodisperse. I could detect by DLS the complex 
of detergent and PelB-Vpu as a narrow peak at 10 
nm. A molecular weight of 448.6 KDa was predicted 
for the protein-detergent complex using this 
technique. Monodispersity of Vpu at a 
concentration of 10 mg/mL is shown by the heat 
map diagram (A) and a plot of frequency of each 
particle size estimated by multiple runs of the 
experiment (B). 
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chromatography to be around 315 
kDa (Figure III-6). This indicates that 
Vpu exists as an oligomer in 
complex with the βDDM micelles. 
The size of empty βDDM micelles 
size of has been estimated to be 60-
70 kDa (Jumpertz et al. , 2011, Prive, 
2007, Strop and Brunger, 2005, 
VanAken et al. , 1986), however, it is 
difficult to predict the size of the 
βDDM-protein micelles. 
Consequently, the accurate 
determination of the oligomeric state 
of the protein is very challenging in a 
protein-detergent micelle complex.  
Preparations of purified Vpu are 
uniform and the protein is folded and 
stable. 
Dynamic light scattering of 
purified Vpu preparations reveals 
very low dispersity at a concentration of 5 mg/mL and 10 mg/mL with a 10.44 ± 0.1 nm 
hydrodynamic radius (data not shown and Figure III-8). This estimation was fairly 
consistent upon re-runs of the experiment as is evident by the histogram depicting the 
frequency of each size estimation over 10 runs (Figure III-8B). The hydrodynamic radius 
Figure III-9: Circular dichroism analysis of PelB-
Vpu. 
CD spectrometry analysis at various temperatures 
(A) reveals that PelB-Vpu is stable upto 40 oC. CD 
spectrometry of the protein at various salt 
concentrations (B) reveals that Pel-Vpu is stable 
across a wide spectrum of salt concentrations. 
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corresponds to a protein-detergent complex of about 332.2 kDa, corresponding well to the 
molecular mass estimates reported above for size-exclusion chromatography. 
Circular dichroism was used to estimate the secondary structure content of Vpu. 
The CD spectrum of Vpu displayed two negative peaks at 208 and 222 nm, characteristic 
of a α-helical protein. Spectra for wavelengths below 200 nm could not be obtained 
because of interference from the chloride ions in the buffer. Analysis of the CD data (in 20 
mM HEPES pH 7.5, 250 mM NaCl, 0.02% βDDM, and 5% glycerol) by CONTINLL in the 
CDPro software package revealed 55.6% right handed helix, 23% left handed helix, 3.3% 
sheets, 2% turns and 16% random elements, corresponding well to in silico analysis by 
the secondary structure prediction tool, GOR 54, which estimated 65.2% helices in the 
sequence. 
Purified PelB-Vpu was observed to be stable up to around 40 ºC after which a 
temperature dependent disintegration of the α-helical secondary structure was observed 
(Figure III-9A). It was also observed that the protein was stable across a wide range of 
salt concentrations (Figure III-9B). 
Purified Vpu can selectively associates with CD4 
The interaction with CD4 and its subsequent degradation is one of the well-
characterized functions of Vpu. This interaction has been shown to be dependent on an 
intriguing combination of specific amino acids and structural features in the 
transmembrane and cytoplasmic domain of both proteins. Scrambling the amino acids of 
the transmembrane domain of Vpu, while preserving its hydrophobicity, decreased its 
capability to down-regulate surface expression of CD4 in HeLa CD4+ cells (Hout et al. , 
2005). This indicates a potential of loss of usual interaction between the two proteins. It 
has also been shown that specific amino acids are required in the cytoplasmic domain of 
CD4 (Lenburg and Landau, 1993) and Vpu for their interaction (Margottin et al. , 1996). 
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Furthermore, it was also 
demonstrated that the formation of 
α-helical structures in the 
cytoplasmic domains of both Vpu 
and CD4 was critical for CD4-Vpu 
interactions (Tiganos et al. , 1997). 
The transmembrane and 
cytoplasmic domains of CD4 were 
expressed with an N-terminal fusion 
with maltose binding protein (MBP) 
in BL21(DE3) E. coli cells. The 
fusion protein embedded in βDDM 
micelles was purified by using metal 
affinity chromatography and size 
exclusion chromatography 
purifications in βDDM micelles (data 
not shown). I was able to 
demonstrate that PelB-Vpu in βDDM 
micelles precipitated with MBP-CD4 (Figure III-10). The exclusivity of the binding was 
illustrated by the fact that PelB-Vpu did not precipitate with MBP nor does it cross react 
with anti- MBP antibody or the agarose beads. It does appear that the affinity of 
interactions between the two proteins is substantial enough to overcome the challenges 
imposed by the fact that both proteins are surrounded by bulky detergent micelles. 
 
 
Figure III-10: Co-immunoprecipitation of Vpu with 
CD4. 
 A fusion of maltose binding protein (MBP) and the 
trans-membrane and cytoplasmic domains of CD4 
was incubated with Vpu. The complex was 
captured by anti- MBP antibodies conjugated with 
beads and pelleted by centrifugation. Vpu was 
pelleted with MBP-CD4 and the samples were 
analyzed by SDS-PAGE followed by coomassie 
staining (A) and immunoblot analysis with 
antibodies raised against Vpu (B). Panel A depicts 
the all the proteins pulled down by the agarose 
beads (Lane 1) and agarose beads conjugated with 
Anti-MBP (Lanes 2-5). Anti-MBP, MBP-CD4, MBP 
and Vpu are denoted by blue, green, red and black 
arrows respectively. In the immunoblot analysis (B), 
Vpu was not detected in Lane 1 (beads with MBP-
CD4), Lane 2 (beads conjugated with anti- MPB 
with MBP and Vpu), Lane 3 (beads conjugated with 
anti- MPB with MBP-CD4), Lane 4 (beads 
conjugated with anti- MPB with Vpu) but, was 
detected in Lane 5 (beads conjugated with anti- 
MPB with MBP-CD4 and Vpu). 
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Conclusions 
The requirement of obtaining substantial quantities of pure, folded, functional and 
monodisperse protein samples has been a major factor that hampers the elucidation of 
structural models of membrane proteins. Here I demonstrate that I was able to express 
good quantities of HIV-1 Vpu. The protein was folded, mono disperse and functional. This 
is in spite of the fact that the signal peptide seems to be uncleaved from the protein. I 
hypothesize that efficient cleavage of the signal peptide was inhibited by the inability of 
the periplasmic peptidases to access the cleavage site. Nevertheless, this expression 
strategy could provide an excellent template towards producing high quality membrane 
proteins towards structural studies. 
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IV. Crystallization of Vpu. 
Abstract 
Viral protein U (Vpu) is an important accessory protein of the Human Immuno-
deficiency Virus (HIV) -1 which is primarily involved in viral release from the host cells and 
viral propagation, using a multi-pronged approach. This protein has some interesting 
structural attributes that are yet to be elucidated on which, there are strong indications, 
that the functions of the proteins could be dependent on. Thus, it is an attractive target to 
structurally characterize using crystallization followed by X-ray diffraction. I had earlier 
reported the successful expression, purification followed by functional and biophysical 
characterization of bacterially produced Vpu with the PelB signal peptide. I was able to 
obtain pure, functional, monodisperse samples of the protein which are excellent 
precursor conditions to satisfy before setting up crystallization trials. In this chapter, I detail 
our efforts to crystallize the protein in detergent micelles. I also employ the relatively new, 
promising technique of crystallizing membrane proteins in a more native environment by 
integrating them in lipid cubic phases. 
Introduction 
Integral membrane proteins, for example, channels, transporters, receptors, are 
critical components of many essential biological processes and make up about 20- 35% 
of the proteins encoded by an organism’s genome. Overexpression of membrane proteins 
for structural studies is a major challenge. During the synthesis of a membrane protein, 
the secretory machinery of the cell is engaged, and that protein must be targeted to and 
inserted into the membrane (de Gier and Luirink, 2001, Johnson and van Waes, 1999, 
Muller et al. , 2001). High-level expression of a membrane protein often saturates the 
secretory pathway, leading either to the buildup of toxic intermediates or to inclusion body 
formation. 
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Having achieved satisfactory levels of expression, the recombinant membrane 
protein must be purified, using standard biochemical techniques. This typically requires 
using detergents to solubilize the membrane protein. The choice of detergent is a critical 
issue to consider while extracting proteins from the membranes and maintain them in 
solution thereafter.  Ideally, a detergent (or detergent mixture) should solubilize the target 
protein in an unaggregated state. It is important to assess the effects of detergent on 
protein stability (Engel et al. , 2002); an appropriate detergent will selectively stabilize the 
native structure of the protein (Rosenbusch, 2001) and also maintain it in its functional 
conformation.  
It is also important that the structural integrity of the protein be maintained and that 
nonspecific aggregates be avoided. Dynamic light scattering could be used to test a 
protein sample for monodispersity to streamline crystallization trials and eliminate less 
favorable samples (Ferre-D'Amare and Burley, 1994). Dynamic light scattering is 
frequently used to evaluate the monodispersity of protein samples prior to crystallization 
trials (Ferré-D'Amaré and Burley, 1997). However, solutions of integral membrane 
proteins could appear polydisperse by dynamic light scattering, owing to the presence of 
detergent micelles which could mimic the size of the protein–detergent complex or form 
heterogeneous protein-detergent complexes. (Hitscherich et al. , 2001).  
Finally, the growth of well-ordered 3D crystals, which is a prerequisite for X-ray 
crystallography, has often been a major challenge, in which case, the presence of 
detergent complicates matters.  Crystallization is driven by the increase of precipitant 
concentration in a drop of protein solution by vapor diffusion. Although protein–protein 
interactions are the most important interactions for obtaining a high-quality of crystal, the 
detergent molecules present in the protein-detergent complex must also be adapted in 
size. Therefore, searching for crystallization conditions for protein–detergent complexes 
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is of paramount importance towards exploring a complicated phase diagram upon which 
protein phase transitions and detergent phase transitions are superimposed and in which 
each component affects the behavior of the other (Garavito and Ferguson-Miller, 2001).  
Crystallizing membrane proteins within a more native lipid bilayer environment was 
achieved when well-diffracting crystals of bacteriorhodopsin were obtained in the 
presence of a lipidic cubic phase (Landau and Rosenbusch, 1996). The lipidic cubic 
mesophases form gel-like materials containing continuous bilayer structures, arranged so 
as to form topologically distinct lipid and aqueous regions (Larsson, 2000, Rummel et al. 
, 1998) which, is a membrane mimetic environment that could be suitable for the 
stabilization and crystallization of membrane proteins. Proteins are first added to 
preformed lipidic cubic phases, upon which they partition into the bilayer. This is followed 
by the addition of precipitating agents to induce crystallization (Figure IV-1) (Caffrey, 2000, 
Nollert et al. , 2002).  
Lipid cubic phase crystallization has been remarkably successful for complex 
transmembrane proteins such as archaeal seven-transmembrane helix proteins, leading 
Figure IV-1: Crystallization of IMPs in LCP.  
Upon the addition of precipitants to proteins reconstituted in LCP, phase separation 
occurs and the protein molecules diffuse from the bilayer environment into a sheet like 
lamellar phase (A).  The proteins start concentrating in the lamellar phase and begin to 
nucleate, leading to crystal growth (B). An expanded view of the bilayer (C) depict the 
protein in blue and green, and the lipids in yellow with tail. The blue color represents the 
aqueous channels. Adapted from Caffrey (2015). 
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to structures for sensory rhodopsin II from Natronobacterium pharaonis (Gordeliy et al. , 
2002, Luecke et al. , 2001, Royant et al. , 2001) and halorhodopsin and bacteriorhodopsin 
from H. salinarum (Kolbe et al. , 2000, Luecke et al. , 1998, Pebay-Peyroula et al. , 1997). 
This technique has been highly successful in crystallization and structure determination of 
human G protein-coupled receptors (GPCRs) (Cherezov et al. , 2007, Chien et al. , 2010, 
Jaakola et al. , 2008, Shimamura et al. , 2011, Wu et al. , 2010). Most of the lipidic cubic 
phase crystals have been grown in hydrated monoolein. However, a variety of other lipid 
species can also be incorporated without causing the disruption of the cubic phase but, 
on the contrary, leading to an expansion in the range of proteins that can be 
accommodated with this technique (Cherezov et al. , 2002). Although data are now 
becoming available detailing which detergents and precipitating agents are compatible 
with the lipid matrix (Ai and Caffrey, 2000, Cherezov et al. , 2001), the method is under 
active development.  
Translational diffusion of membrane proteins embedded in LCP matrix is essential 
for crystal nucleation and growth. The structural features of LCP, however, can restrict 
motions of large proteins or oligomeric protein aggregates, thus preventing their 
crystallization. Fluorescence recovery after photo-bleaching (FRAP) was used to study 
the diffusion of integral membrane proteins in LCP (Cherezov et al. , 2008). It was found 
that the diffusion properties within LCP matrix strongly depend on protein stability and 
screening conditions. Common precipitants often induce fast non-specific aggregation of 
membrane proteins, limiting their mobility within LCP, and thereby impeding their chances 
for crystallization. A good correlation between a high protein mobile fraction and 
successful crystallization conditions has been observed. Based on these studies, a high 
throughput pre-screening assay (HT LCP-FRAP) was developed. This assay can be used 
to select the most promising protein construct, ligand and LCP host lipid, and rule out 
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conditions that are not conducive to diffusion from subsequent crystallization trials (Xu et 
al. , 2011). HT LCP-FRAP was instrumental in obtaining initial crystallization conditions 
for the CXCR4 chemokine and dopamine D3 GPCRs (Chien, Liu, 2010, Wu, Chien, 2010). 
As discussed in Chapter III, I was able to obtain sufficient amounts of extremely 
pure, functional, monodisperse samples of PelB-Vpu in bDDM micelles. The protein 
detergent complex was stable across various salt concentrations and up to approximately 
40 ºC. These presented me with very favorable parameters to set up wide range of 
experiments towards my efforts to crystallize PelB-Vpu. 
Materials and Methods 
Setting up sitting- drop crystallization trials.  
Expression, purification and characterization of PelB-Vpu was described in 
Chapter III. A Rigaku CrystalMation high-throughput machine, was used to disperse 0.1 
µL and 0.2 µL of PelB-Vpu from a stock of 10 mg/mL of protein into each of the mini-wells 
of a 2 drop 96 well crystallization plate (Molecular Dimensions, cat# MD11-00U-100). 
Similarly, 0.1 µL of each of the 96 crystallization conditions were dispersed into the mini-
wells such that one of the mini-well had a protein to precipitant ratio of 1:1 (v/v) and the 
other had a ratio of 2:1 (v/v). 50 µL of the corresponding crystallization conditions were 
dispersed in the reservoir for each of the 2 drops with the same condition. The plates were 
sealed tightly and incubated at 20 ºC. The wells were monitored by visualizing them under 
UV and polarized light microscopes. A variety of commercial crystallization screens were 
used, such as, Crystal screen HT (Hampton Research, cat# HR2-130), Natrix HT 
(Hampton Research, cat# HR2-131), Index HT (Hampton Research, cat# HR2-134), 
MembFac HT (Hampton Research, cat# HR2-137), PEG/Ion HT (Hampton Research, cat# 
HR2-139), GridScreen Salt HT (Hampton Research, cat# HR2-248), MemGold (Molecular 
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Dimensions, cat# MD1-39), MemGold2 (Molecular Dimensions, cat# MD1-63), The PEGs 
(Qiagen, cat# 130704), The Classics (Qiagen, cat# 130701), The MbClass (Qiagen, cat# 
130711), The MbClass II (Qiagen, cat# 130712), and MPD (Qiagen, cat# 130706).     
Labeling PelB-Vpu for LCP-FRAP. 
Cy3-mono NHSester dye (GE Healthcare Life Sciences, cat# PA13101) was 
prepared as a 5 mg/mL stock in dimethylformamide (DMF, Sigma, cat# D-4254). 10 mg 
of PelB-Vpu in bDDM micelles, purified by size exclusion chromatography as described in 
Chapter III, was incubated with 10 µg of Cy3-mono NHSester dye. The labelling reaction 
was incubated for 3 hr in the dark at 4 ºC and was loaded onto a 1.5 mL bed volume Talon 
metal affinity resin, which was prequilibrated with a buffer consisting of 20 mM HEPES pH 
7.5, 250 mM NaCl, 0.02% bDDM. The column was washed with 20 column volumes of the 
same buffer to remove unbound and weakly bound dyes and the labelled protein was 
eluted with buffer supplemented with 300 mM imidazole. The labelled protein was 
concentrated to 10 mg/mL before setting up LCP-FRAP experiments. The metal affinity 
purification and concentration of the labelled samples were performed at 4 ºC in dark to 
preserve the functional integrity of the dye.  
Setting up LCP crystallization and LCP FRAP plates. 
PelB-Vpu complexed with bDDM micelles and 1-Oleoyl-rac-glycerol (Monoolein) 
(Sigma, Cat# M7765) were mixed using two Hamilton micro-syringes connected by a 
coupler. The protein-detergent complex was placed in one syringe and monoolein was 
placed in the other such that the next mixture contained 60% monoolein and 40% protein 
by weight. Mixing was achieved by repeatedly moving the contents of the two syringes 
back and forth through the coupler. For dispensing the homogeneous mesophase onto 
glass sandwich crystallization plates, the coupler was replaced by a needle and 0.1 µL 
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was dispensed onto each well by a Gryphon high-throughput LCP screen set up machine 
by Art Robbins Instrument. Precipitant solutions (1 µL) of various compositions were 
placed over the mesophase and the wells were finally sealed with a cover glass. The 
screens were incubated at 20 ºC for one week before monitoring for crystal growth. 
Commercial screens used for this process include Crystal screen HT (Hampton Research, 
cat# HR2-130), MembFac HT (Hampton Research, cat# HR2-137), PEG/Ion HT 
(Hampton Research, cat# HR2-139), MemGold (Molecular Dimensions, cat# MD1-39), 
MemGold2 (Molecular Dimensions, cat# MD1-63), The PEGs (Qiagen, cat# 130704), The 
MbClass II (Qiagen, cat# 130712), and MPD (Qiagen, cat# 130706). 
Setting up LCP-FRAP Experiment 
In order to set up LCP FRAP plates, the labelled protein sample was used at a 
concentration of 10 mg/mL. The protein was incorporated into LCP and 96 well screening 
tray was set up with different precipitants as mentioned above. The 96 different conditions 
were based of StockOptions Salt screen (Hampton Research, cat# HR2-245). The 48 
different salts were used at 100 mM and 400 mM concentrations, and combined with a 
buffer (100 mM TRIS, pH 7), and a precipitant such as polyethylene glycol 400 (30% v/v). 
The screens were incubated at 20 ºC for 1 day. 
LCP-FRAP data collection 
LCP-FRAP data acquisition and image analysis were fully automated using the 
Formulatrix benchtop FRAP machine. Each well was sequentially bleached at an 
automatically chosen location in the drop by firing laser pulses at a 25 Hz pulse rate. 
Fluorescence images before and immediately after bleaching were recorded and saved 
for further analysis. After bleaching all the 96 wells (approximately 30 min incubation time 
for each well), the plate was scanned to record the end-state fluorescence r
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images for each sample. Recorded images were processed automatically to locate the 
bleached spot and to calculate the intensity of the recovered fluorescence. Conditions 
above 30% recovery were chosen and the pattern of recovery was analyzed individually 
over 1000 sec.  
Dynamic light scattering 
Dynamic light-scattering (DLS) measurements were performed using a NaBiTec 
GmbH setup comprising a SpectroSize 302 (Molecular Dimensions) in combination with 
an S6D microscope (Leica). PelB-Vpu was purified by size exclusion chromatography and 
concentrated to 10 mg/mL as described in Chapter II and then was illuminated in a 2 µL 
hanging drop using a 24-well crystallization plate (VDX Greased Plate, Hampton 
Research) covered with siliconized-glass circular cover slides (22 mm; Hampton 
Research). The well itself was filled with 400 µL SEC running buffer. Prior to the 
measurement, the protein solution was centrifuged at 18000 ×g, 30 min, 4 ºC to remove 
possible dust and other suspended particles. All measurements were done at 20 ºC. Ten 
consecutive measurements, each with an integration time of 20 s, were averaged. 
Hydrodynamic size of the particles was estimated with the instrument software using the 
following parameters: refractive index 1.33, viscosity 1.006, shape factor 1.0 and hydrated 
shell 0.2 nm.   
Results and Discussion 
Conventional crystallization trials resulted in amorphous precipitates. 
PelB-Vpu in complex with bDDM micelles was previously shown to be pure, mono-
disperse and in a functionally active conformation. These are very promising conditions to 
go into experiments screening for conditions for crystallization of the protein detergent 
complex. I observed that, in the majority of the wells, the protein immediately precipitated 
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upon the addition of the precipitating conditions. Upon visualization on subsequent days, 
I could not isolate any promising conditions to fine tune our crystallization attempts and 
mostly yielded amorphous precipitates. Precipitates usually consists of denatured 
proteins. But, they could also contain precipitates of nanocrystals (<1 µm) which can be 
too small to be detected by optical microscopes. Second order nonlinear imaging of chiral 
crystals (SONICC), a method based on the principle of second harmonic generation, has 
been used for the efficient detection of protein nanocrystals (Haupert and Simpson, 2011, 
Wampler et al. , 2008). Recent advancement in detection of protein nanocrystals 
demonstrates that protein nanocrystals, which are first visualized by SONICC, retain the 
ability to dissolve after dilution of the reservoir solution while a denatured precipitate does 
not (Dörner et al. , 2016). But, since SONICC is most efficiently applied to proteins 
containing chromophoric cofactors, Vpu was invisible to any SONICC signals. Hence I 
was unable to characterize wells, such as in Figure IV-2, for the presence of protein 
nanocrystals.  
Figure IV-2: Potential nano-crystals in precipitate obtained by sitting drop vapor diffusion 
crystallization trials.  
Purified, mono - dispersed sample of PelB-Vpu, expressed from BL21- pTM875, at a 
concentration 10 mg/mL and was used in a 2:1 (v/v) ratio with 0.8M ammonium sulfate, 
0.1M citric acid at pH 5. The well was imaged by bright field microscope (A), UV 
microscope (B) and a polarized light microscope (C). 
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The precipitants that were used to induce crystallization could have profound 
effects on detergent phase behavior which could lead to inducing or changing the position 
of phase separations (Garavito et al. , 1996, Rosenow et al. , 2001). One such 
consequence of detrimental phase behaviors could be a scenario where the solution 
separates into detergent rich and detergent poor states at the cloud point boundary. 
Figure IV-3: Heat map diagram representing DLS of 10 mg/mL PelB-Vpu over time at 20 
ºC.  
The sample showed as a narrow peak after freshly concentrating the protein, indicating 
a mono-disperse protein population, day 0 (A). I observe a broadening of the peak 
around day 2 (B) and then gradual appearance of high molecular weight aggregates 
around day 4 (C) and day 6 (D). 
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Integral membrane proteins like Vpu 
will partition into the detergent-rich 
phase(Ward et al. , 1987), where a 
substantial increase in detergent 
concentration can lead to 
denaturation of the protein and be 
deleterious to crystal growth.  
Another factor that could play 
a big role in the eventual 
crystallization of the protein is the 
stability of the protein in the 
detergent micelles at high 
concentrations over time. Dynamic 
light scattering characterization of 
PelB-Vpu at 10 mg/mL concentration reveals that the protein is relatively unstable over 
time (Figure IV-3). I observe from the heat-map diagram that the sharp band at 10 nm , 
indicating a monodisperse PelB-Vpu-bDDM complex when the crystallization trials were 
set up, progressively disintegrates and there is a shift towards a 100 nm particle over time. 
Analysis of a sample by size exclusion chromatography also reveals similar trends (Figure 
IV-4). With increasing time, in units of days, I observe higher amounts of aggregates which 
elute at the void volume of the column (8 mL). Furthermore, I also observe splitting of the 
otherwise single peak in case of the 6th day sample. These indicate towards an unstable 
protein-detergent complex at higher concentrations, and this tendency to aggregate could 
make the prospect of the protein-detergent complex forming crystals, quite challenging. 
The DLS and SEC results of each time point, when compared to each other, also reveals 
Figure IV-4: FPLC-SEC of concentrated PelB-Vpu 
over time.  
50 µL of a sample of 10 mg/mL PelB-Vpu in bDDM 
micelles was injected in to a Superdex 200 10/300 
GL column after 2, 4 and 6 days of setting up a 
crystallization trial with freshly purified and 
concentrated protein. The mobile fraction constists 
of 20 mM HEPES pH 7.0, 250 mM NaCl, 0.02% 
bDDM and 5% glycerol. Void volume aggregates 
are found at 8 mL which is observed to increase in 
amount over time. 
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a concentration dependent dynamic shift in the oligomerization status of the protein. The 
DLS result shows a strong shift towards a 100 nm radius particle over time from a 10 nm 
radius particle size on day 0. This could indicate that at a constant high concentration, 
there is a strong tendency towards protein aggregation, forming high molecular weight 
species over time. But, when the samples are diluted as a result of the mobile phase of 
SEC, even if I do observe a greater proportion of void volume aggregates over time, most 
of the protein till day 4 elutes as a single major peak, same as the fresh sample. From 
these results, I could hypothesize that most of the aggregation of the protein at high 
concentrations is reversible upon dilution. Probability of crystallization could thus be 
increased by finding conditions which increase the stability of PelB-Vpu at high 
concentrations.     
Diffusion in LCP 
With indications that PelB-Vpu may be unstable at higher concentrations in bDDM 
micelles, I decided to explore the possibility of crystallizing the protein in a more native 
environment. Lipid cubic phase (LCP) is a membrane-mimetic matrix which stabilizes 
integral membrane protein and has proved to be a robust approach for crystallizing 
membrane proteins for structure determination. But, for crystal nucleation and growth in 
the LCP matrix, the membrane proteins are required to translationally diffuse within the 
matrix. Thus, large proteins or multi-order oligomeric proteins, with their restrictive rates 
of diffusion would find it very difficult to crystallize. Indeed, there exists correlation between 
the degree of mobility of protein in the LCP and success of crystal formation for a given 
condition. Thus, I used fluorescence recovery after photo-bleaching (FRAP) to investigate 
the manner of diffusion of PelB-Vpu in the LCP under the effects of various crystallization 
conditions. The results obtained depicts that only two conditions (G2 and H4) showed 
moderate levels of diffusion (Figure IV-5). Highly mobile proteins have a value close to 1. 
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There were three other conditions 
which facilitated lower rates of 
diffusion (F3, G6 and H1). A curve 
depicting the fraction of fluorescence 
recovered over time is an excellent 
way of avoiding false positives 
(Figure IV-6). An exponential curve 
is indicative of protein diffusion in the 
LCP. Hence I was optimistic about 
the prospects of a few conditions, 
which showed decent levels of 
protein mobility in the LCP, as determined by LCP-FRAP, towards being amiable to 
crystallization. 
LCP crystallization screen yielded no promising conditions. 
Crystallization of proteins by the lipid cubic phase technique has resulted in 
structural models of a wide variety of proteins such as microbial rhodopsins, GPCRs, 
photosynthetic proteins, small peptides, heme-copper oxidases and bacterial outer 
membrane proteins (Cherezov, 2011). In spite of extensive screening, I was unable to 
identify any condition that showed any degree of promise towards obtaining well- 
diffracting crystals. Unlike the more traditional methods of crystallization of proteins, where 
membrane proteins typically nucleate by virtue of their soluble domains (type II crystal 
packing), lipid cubic phase crystallization facilitates the interaction of both the soluble and 
the hydrophobic transmembrane domains of a membrane protein (type I crystal packing) 
(Caffrey, 2000, Caffrey, 2009, Cherezov, Rosenbaum, 2007, Tiefenbrunn et al. , 2011). 
Hence, the fact that Vpu lacks a prominent soluble N-terminal domain was seen as a less 
Figure IV-5: Fraction of fluorescence recovered 
after photo-bleaching for the 96 conditions. 
Highly mobile species would have a value close to 
1. The conditions marked “i" were further probed for 
the nature of fluorescence recovery over time to 
eliminate false positives.   
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of a hindrance when crystallizing the proteins in LCP. But, I speculate that the presence 
of the hydrophobic PelB signal peptide with Vpu could play a role in non- homogeneous 
insertion of PelB-Vpu in lipid bilayers. This not only could have resulted in lower 
percentage of conditions being successful with LCP FRAP, but also could be a very 
detrimental factor towards nucleation and crystal growth of the conditions that showed 
appreciable amounts of mobility. A known disadvantage of LCP matrices is the curved 
nature of the lipid membranes. The resulting microstructures could limit the ability of larger 
membrane proteins to diffuse freely and thus hamper the chances of crystallization 
(Cherezov et al. , 2006). Although this problem has been circumvented by the addition of 
Figure IV-6: Fluorecense recovery data for PelB-Vpu in LCP under different conditions. 
Condition H5 was used as a negative control (A). In condition G6 (100 mM TRIS, pH 7.0; 
400 mM potassium phosphate dibasic, 30% PEG400 (v/v)) PelB-Vpu in LCP 
demonstrates moderate levels of diffusion (B). Conditions  H4 (100 mM TRIS, pH 7.0; 
400 mM sodium phosphate dibasic, 30% PEG400 (v/v)) and G2 (100 mM TRIS, pH 7.0; 
400 mM potassium citrate tribasic, 30% PEG400 (v/v)) show higher levels of diffusion of 
PelB-Vpu in LCP, (C) and (D) respectively. 
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non-volatile alcohols, low molecular weight PEGs and polymers that lead to the swelling 
of the LCP (Cherezov, Clogston, 2006, Wadsten et al. , 2006), the uncertainty that shrouds 
the manner of interaction between PelB-Vpu and the lipid complicates the scenario.  
Conclusions 
Although there have been significant advances in membrane protein 
crystallization, the crystallization of PelB-Vpu has proven to be incredibly challenging. The 
lack of any promising conditions that could lead to formation of crystals, in spite of 
extensive screening, prompts us to revisit our strategy of protein expression, especially 
the presence of the hydrophobic PelB signal peptide. It would be interesting to structurally 
characterize PelB-Vpu in solution using techniques such as nuclear magnetic resonance 
(NMR) spectroscopy that could elucidate key details on the effect that the hydrophobic 
signal peptide could have on the protein in general. This would also guide us onto learning 
about the prospects of this expression strategy and/or help us design effective strategies 
for crystallization of Vpu.  
Figure IV-7: Image of a well from the LCP crystallization trials. 
Purified, mono - dispersed sample of Vpu at a concentration of 10 mg/mL and was mixed 
in a ratio of 2:3 with 1 – Oleoyl – rac – glycerol to integrate PelB-Vpu into lipid cubic 
phases. Then, crystallization trials were set up with various crystallization conditions. The 
well shown used 0.1M bicine, pH 8.9, 31% w/v PEG 2000 and imaged by a polarized light 
microscope (A), bright field microscope (B) and UV microscope (C). Although the 
polarized light image showed some potential of crystal formation, the contents of the well 
were UV invisible. 
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V. Characterization of Vpu using Nuclear Magnetic Resonance (NMR) 
Spectroscopy 
Abstract 
Vpu is an HIV-1 protein that is essential for virus propagation in vivo where it 
performs important functions that promote virion assembly and egress. It belongs to the 
viroporin protein family encompassing small homo-oligomeric ion channel proteins with 
members in many of the most successful human viruses (influenza, coronaviruses). In 
addition to its ion-transport function, Vpu exhibits affinity to various cellular proteins, 
including HIV-1’s receptor (CD4) and a major host restriction factor (tetherin). With its 
multiplicity of functions, Vpu represents a promising, underexplored target for drug 
development. Nuclear magnetic resonance (NMR) spectroscopy is a perfect technology 
to study Vpu’s structure and function. Our extensive crystallization experiments of protein-
detergent micelles of PelB-Vpu have not been successful, whereas, NMR studies by other 
groups have revealed a great deal of structural information. Moreover, most of the 
ascribed functions of Vpu involve protein-protein interactions – either with itself in forming 
oligomers, or with the cellular targets mentioned above. These interactions involve both 
the transmembrane and cytoplasmic tail domains of the proteins that are suspected to 
exhibit conformational flexibility. In this study, I present the results of an evaluation of the 
conformational integrity of PelB-Vpu in different membrane mimetic environments. 
Introduction 
HIV-1 and its closest simian relative SIVcpz express a small hydrophobic protein 
called viral protein U (Vpu) (Cohen et al. , 1988, Strebel et al. , 1988), which is not found 
in most of the other known primate lentiviruses (e.g. HIV-2 and most SIVs) (Strebel, 2014, 
Yang et al. , 2010). Vpu is vital for efficient virus propagation in vivo and is considered a 
major factor in the rapid evolution of HIV-1 from a relatively ineffective zoonotic pathogen 
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to the successful pandemic-causing agent that we know today (Andrew and Strebel, 2010, 
McCarthy and Johnson, 2014, Sauter et al. , 2009, Yang, Lopez, 2010). It is a 16-kDa type 
III trans-membrane protein of 77-86 amino acids in length depending on the HIV-1 
subtype. Vpu has a very short N-terminal extracellular domain; a trans-membrane domain 
(TMD) and a longer cytoplasmic domain (CTD) which has two predicted α-helical regions 
separated by a hinge. The hinge region contains two phosphorylation sites (Schubert et 
al. , 1992) and is partially responsible for the flexibility of the CTD (Wittlich et al. , 2009). 
Vpu plays a number of roles in promoting virion assembly and release (Dube et al. 
, 2010, Roy et al. , 2014, Strebel, 2014). Vpu functions through protein-protein interactions 
to down-regulate key host-cell proteins (Andrew and Strebel, 2010). More specifically, Vpu 
interacts with the CD4 surface receptor through their respective TMDs, causing the 
retention of the receptor in the ER (Magadan and Bonifacino, 2012, Magadan et al. , 2010). 
Subsequently, the CTD recruits ubiquitination factors that mark CD4 for proteosomal 
degradation(Magadan and Bonifacino, 2012, Magadan, Perez-Victoria, 2010). Similar 
mechanisms were invoked for the roles that the Vpu TMD and CTD play in the 
downregulation of tetherin, an integral membrane protein that functions to limit the escape 
of newly formed virions from cells infected by HIV-1 and other enveloped viruses (e.g. 
Ebola) (Douglas et al. , 2010, Evans et al. , 2010, Kluge et al. , 2013, Kueck and Neil, 
2012). In addition, the CTD of Vpu directly functions to displace tetherin away from the 
sites of viral assembly in the host cell membrane (McNatt et al. , 2013).  
The importance of Vpu for efficient assembly and egress of HIV-1 (Giese and 
Marsh, 2014, Jafari et al. , 2014, Pickering et al. , 2014) makes it a promising, but so far 
underexplored, therapeutic target. Developing its therapeutic utility requires establishing 
reliable structural information. The Vpu CTD and TMD have been studied by solution and 
solid state nuclear magnetic resonance spectroscopy (NMR) resulting in independent 
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structures of the CTD or TMD (Sharpe et al. , 2006, Wittlich, Koenig, 2009) which have 
been combined in a molecular model (Lemaitre et al. , 2006). A full-length NMR structure 
of the protein was recently elucidated (Zhang et al. , 2015). Interestingly, the relative 
mobility of the cytoplasmic helices was dependent on the membrane mimetic 
environments used. In 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
proteoliposomes, the helices were flexible and could be either arranged in a linear or in a 
U -shaped orientation as against in 1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC) 
micelles, where the backbone dynamics were more restricted and the cytoplasmic helices 
adopted well-defined U-shaped loop region between them.  
It was also notable in the full-length structure that the transmembrane domain 
influences the conformation, structure and dynamics of the C-terminal domain and vice 
versa. Hence our goal was to characterize the PelB-Vpu protein, described in Chapter III, 
by NMR spectroscopy for its structural attributes. Additionally, while the individual domains 
and the full length Vpu were studied in form of monomers, I have strong evidence that the 
full length Vpu forms oligomers. Vpu belongs to a diverse group of small transmembrane 
viral proteins called viroporins that form homo-oligomeric ion channels. While Vpu’s 
channel activity has been well demonstrated (Ewart et al. , 1996, Herrero et al. , 2013), its 
physiological role is less clear (Strebel, 2014). NMR experiments could also explain why 
conventional crystallization attempts have failed so far in case of PelB-Vpu and indicate 
towards more promising crystallization strategies.  
Materials and Methods 
Expression of PelB-Vpu and MBP-Vpu in M9 minimal media. 
An E. coli vector (pTM875) directing the expression of PelB-Vpu was described in 
Chapter III. 1 mL of LB media supplemented with 1 μg/mL kanamycin (Phytotechnology 
lab; cat# K378) was inoculated with a colony of BL21- pTM875 or BL21- pTM975 
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(described in Chapter II) and was grown for about 8 hr at 37 ºC at 170 rpm agitation. M9 
minimal media was prepared with 45 mM Na2HPO4, 22 mM KH2PO4, 8.5 mM NaCl and 
20 mM NH4Cl (Sambrook and Russell, 2001). The media was autoclaved and 
supplemented with 1x MEM vitamin mix (Sigma; cat# M6895), 2 mM MgCl2, 0.1 mM CaCl2 
and 0.4% glucose. Supplements were sterilized using a 0.45 µm filter. M9 minimal media 
(100 mL) was inoculated with the LB-kanamycin- overnight-grown culture (5 µL or a ratio 
of 1:20,000) and was incubated overnight at 37 ºC at 170 rpm. This overnight culture was 
used to inoculate a 1 L culture, which constituted of 20 mM 15NH4Cl (Cambridge Isotope 
Laboratories, Inc; cat# NLM-467) instead of NH4Cl, at a ratio of 1:100 that was grown at 
37 ºC at 170 rpm until culture density reaches OD600 ≈ 0.4. The culture was then moved 
to 15 ºC and bacteria were allowed to grow until density reached OD600 ≈ 0.5. At this point, 
recombinant Vpu expression was induced by addition of IPTG (Roche; cat# 11411446001) 
to a final concentration of 0.2 mM. in case of BL21- pTM875 and 0.4 mM IPTG in case of 
BL21 cells harboring pTM975, an E. coli expression vector directing the expression of 
MBP-PPCS-Vpu as described in Chapter III, and incubated at 15 ºC for 14 hr with 170 rpm 
agitation. The cells were harvested by centrifugation at 7000 xg at 4 ºC for 20 min and 
stored at -20 ºC until further use.  
Membrane isolation 
Bacterial cells were harvested by centrifugation cultures (4 L of culture yielded 
approximately 12 g of pelleted cells) and then  re-suspended in 100 mL of ice-cold 
phosphate buffer saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4) supplemented with EDTA-Free SIGMAFAST™ Protease Inhibitor 
Cocktail tablets (Sigma; cat# S8830), to prevent protein degradation. The cells were lysed 
by double passage through a microfluidizer (Microfluidics Microfluidizer). The lysate was 
collected and centrifuged at 36,000 ×g for 30 min at 4 ºC. The insoluble fraction was 
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washed once by repeated re-suspension (50 mL of ice-cold PBS with protease inhibitor 
cocktail) and centrifugation. The pellet was frozen at -80 ºC until further use. 
Detergent extraction 
For large-scale extractions from 4L cultures, the pellet, containing the membrane 
fraction, was fully re-suspended in 100 mL PBS supplemented with EDTA-Free 
SIGMAFAST™ Protease Inhibitor Cocktail tablets. N-Dodecyl-N,N- dimethylglycine 
(Empigen BB, Sigma; cat# 30326) was used for solubilization at a final concentration of 
3% (w/v). The protein was extracted and at 4ºC overnight with agitation at 200 rpm. The 
detergent soluble fraction was obtained by collecting the supernatant after centrifugation 
at 36,000 ×g for 30 min at 4 ºC. 
Purification 
A gravity driven column (Biorad Econo-column) containing TALON® Superflow 
metal affinity resin (15 mL bed volume, Clontech Laboratories Ltd; Cat# 635507) was 
equilibrated with binding buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 1.5% Empigen, 5 
mM imidazole). The sample was then loaded onto the column, flow-through was collected 
and reloaded onto the same column to collect the final flow-through. The column was 
sequentially washed with ten bed volumes each of wash buffers containing various 
combinations of salt and imidazole, for example, for expression from pTM875, 20 mM 
HEPES pH 7.5 with 500 mM NaCl (Wash I), 500 mM NaCl, 1.5% Empigen (Wash II), 250 
mM NaCl, 1.5% Empigen (Wash III), 250 mM NaCl, 1.5% Empigen, 5 mM imidazole 
(Wash IV) and 250 mM NaCl, 1.5% Empigen, 5% glycerol, 10 mM imidazole (Wash V) to 
remove weakly bound proteins. Tightly bound proteins were eluted by application of 3 bed 
volumes of elution buffer (20mM HEPES pH 7.5, 250 mM NaCl, 1.5% Empigen, 5% 
glycerol, 300 mM imidazole). When purifying the protein produced using pTM975, wash 
buffers IV and V were replaced with wash buffers VI and VII, respectively. They contained 
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20 mM HEPES pH 7.5, 250 mM NaCl, 1.5% Empigen supplemented with 10 mM imidazole 
(Wash VI) and with 15 mM imidazole and 5% glycerol (Wash VII).  
The eluted sample was concentrated by 30 kDa molecular weight cutoff (MWCO) 
concentrators (Millipore; cat# UFC903024) to approximately 10 times its original volume. 
Concentrated samples were further purified by size exclusion chromatography (GE Life 
sciences, Superdex 200 10/300 GL; column volume: 24 mL; fluid phase: 8 mL) using a 
fast pressure liquid chromatography instrument (FPLC, Pharmacia, Äkta Explorer). The 
running buffer contained 20 mM HEPES pH 7.5, 250 mM NaCl, 1.5% Empigen, and 5% 
glycerol. For preparatory separations, a 1 mL sample of concentrated Vpu was loaded 
onto the SEC column and chromatography was performed at a flow rate of 0.5 mL/min. 
The protein elution was detected by absorption at 280 nm. The concentration of protein in 
the desired peak was determined spectrophotometrically (A280) based on the primary 
sequence of Vpu; Σ280 was calculated with ProtParam web application 
(http://web.expasy.org/protparam/).  
Detergent exchange  
A gravity driven column (Biorad Econo-column) containing 1 mL bed volume of 
TALON® Superflow metal affinity resin (Clontech laboratories Ltd; Cat# 635507) was 
equilibrated with binding buffer (20 mM HEPES pH 7.5, 250 mM NaCl, 1.5% Empigen). 
Purified PelB-Vpu- Empigen complex was then loaded onto the column, flow-through was 
collected and reloaded onto the same column to collect the final flow-through. The column 
was washed with twenty bed volumes of a wash buffer containing 20 mM HEPES, pH 7.5, 
250 mM NaCl, 5% glycerol and the detergent of choice for NMR spectroscopy, for 
example, LysoFosCholine 16 or 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphocholine 
(LPPC) (Anatrace, cat# L216), LysoFos Glycerol 16 or 1-Palmitol-2-Hydroxy-sn-Glycero-
3-Phospho-(1'-rac-Glycerol)-Sodium Salt (LPPG) (Anatrace, cat# L316), 1,2-Dihexanoyl-
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sn-Glycero-3-Phosphocholine (DHPC) (Anatrace, cat# D606) and LysoFos Glycerol 14 or 
1-Myristoyl-2-Hydroxy-sn-Glycero-3-Phospho-(1'-rac-Glycerol) -Sodium Salt) (LMPG) 
(Anatrace, cat# L314). The critical micelle concentration (CMC) of each of the detergents 
and the concentrations used to solubilize Vpu are shown in Table V-1. The wash buffer 
was applied one bed volume at a time to obtain most effective detergent exchange without 
consuming excess detergents. Protein was eluted with 2 bed volumes of the same wash 
buffer, supplemented with 300 mM imidazole.  
Table V-1: Ionic properties and CMCs of detergents used in the study. 
Detergents Charge CMC (mM) 
Concentration 
Used (mM) References 
Empigen BB Zwitterionic 1.8 5 
(Beckett and 
Woodward, 1963) 
LysoFosCholine 16 
(LPPC) 
Zwitterionic 
0.004
-
0.008 
0.03 
(Kumar and 
Baumann, 1991, le 
Maire et al. , 2000, 
Stafford et al. , 1989) 
LysoFos Glycerol 16 
(LPPG) 
Anionic 
0.02-
0.6 
1.2 
(Chou et al. , 2004, 
Stafford, Fanni, 1989) 
1,2-Dihexanoyl-sn-
Glycero-3-
Phosphocholine 
(DHPC) 
Zwitterionic 15 30 
(Chou, Baber, 2004, 
Lin et al. , 1986) 
LysoFos Glycerol 14 
(LMPG) 
Anionic 0.2-3 5 
(Stafford, Fanni, 
1989) 
n-
Dodecylphosphocholi
ne (DPC) 
Zwitterionic 1.5 3 
(Lauterwein et al. , 
1979, le Maire, 
Champeil, 2000) 
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To purify and exchange PelB-Vpu into n-Dodecylphosphocholine (DPC, Anatrace, 
cat# F308S) micelles, a gravity driven column containing 15 mL bed volume of TALON® 
Superflow metal affinity resin was equilibrated with binding buffer (20 mM HEPES pH 7.5, 
500 mM NaCl, 1.5% Empigen, 5 mM imidazole). The Empigen-extracted protein sample 
from the non-aqueous fraction of BL21-pTM875 was then loaded onto the column, flow-
through was collected and reloaded onto the same column to collect the final flow-through. 
The column was sequentially washed with ten bed volumes each of wash buffers 
containing various combinations of salt, DPC and imidazole concentrations, for example, 
20 mM HEPES, pH 7.5 with 500 mM NaCl (Wash I), 500 mM NaCl, 0.2% DPC (Wash II), 
250 mM NaCl, 0.1% DPC (Wash III), and 250 mM NaCl, 0.1% DPC, 10 mM imidazole 
(Wash IV) to remove weakly bound proteins. Tightly bound proteins were eluted by 
application of 3 bed volumes of elution buffer (20mM HEPES pH 7.5, 250 mM NaCl, 0.1% 
DPC, 5% glycerol, 300 mM imidazole). 
Solution NMR experiments. 
Solution NMR experiments were performed on a Bruker Avance III HD 850 MHz 
spectrometer, equipped with 5 mm TCI cryoprobes. Transverse relaxation optimized 
spectroscopy – heteronuclear single quantum coherence (15N-TROSY-HSQC) 
experiments were performed at 40 ºC except for PelB-Vpu in LPPG micelles which were 
performed at 45 ºC. I used 416 transients to obtain a desired signal to noise ratio for 15N-
TROSY-HSQC experiments for PelB-Vpu in DHPC, LPPG and DPC micelles and 160 
transients for similar experiments on PelB-Vpu in LMPG micelles. All protein – detergent 
complexes were held in a solution of 20 mM sodium phosphate, pH 6.5 with 0.5 mM EDTA. 
The data acquisition size (TD) used for all the experiments was 128 and 2048 along the 
15N and 1H dimensions respectively. The raw NMR data was processed using NMRPipe 
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(Delaglio et al. , 1995) and analyzed using the CcpNmr software suite (Vranken et al. , 
2005). 
Cyanogen bromide digestion of PelB-Vpu. 
To digest PelB-Vpu with cyanogen bromide (Gross and Witkop, 1961) a protocol 
was adopted which was amenable to digestion in buffer containing 20 mM HEPES pH 7.5, 
250 mM NaCl, 1.5% Empigen, and 5% glycerol (Andreev et al. , 2010). Briefly, the buffer 
containing the purified protein was acidified by adding HCl up to a final concentration of 
0.5 M. 1 mM PelB-Vpu was digested with 100 mM cyanogen bromide for 16 hr at room 
temperature, in dark. Cyanogen bromide was removed post-reaction by washing with 
fresh buffer over a 3 kDa molecular weight cutoff (MWCO) concentrators (Millipore; cat# 
UFC900324).  
SDS-PAGE gel electrophoresis, staining and immunoblot analysis were done as 
described in Chapters II and III.  
Results and Discussion 
Expression of Vpu in bacteria grown on minimal medium 
Biomolecular NMR studies require the use of isotopically labeled samples obtained 
from cells grown in minimal (M9) medium to ensure isotopical uniformity. I initially 
substituted LB medium with unlabeled M9 medium using our optimized culture protocols 
to reduce costs. The switch resulted in longer generation times of the bacteria. Since 
glucose was used as the only source of carbon in the media, I anticipated a repressive 
effect on the lac operon system on our expression vectors. To counter this, I used IPTG 
at higher concentrations than what I previously used to express the protein from the same 
expression vector in rich media. Hence 0.2 mM IPTG was used to induce expression of 
recombinant PelB-Vpu in bacterial cells, which were grown to mid- logarithmic phase. I 
used the same line of thought to induce bacterial cells harboring pTM975 with 0.4 mM 
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IPTG. Due to the metabolic challenges presented to the bacterial cells by growing them in 
minimal medium, I also anticipated a reduced rate and yield of recombinant protein 
synthesis. This led us to prolonging the time of incubation post- induction with IPTG for 
both the bacterial cultures. Following lysis of the cells by a microfluidizer, cellular 
components were fractionated into aqueous and non-aqueous fractions and the proteins 
were resolved by SDS-PAGE. Immunoblot analysis of such fractions of BL21- pTM975 
revealed that most of desired protein separated in the non-aqueous fraction, which was 
extractable by detergents (Figure V-1).  
Detergent extraction of Vpu 
As described in Chapter III, I have identified βDDM as a suitable membrane mimic 
for PelB-Vpu. However, βDDM forms large micelles (Jumpertz et al. , 2011, Prive, 2007, 
Strop and Brunger, 2005, VanAken et al. , 1986), decreasing experimental resolution and 
sensitivity and is therefore not compatible with NMR studies (Columbus et al. , 2009).  For 
the purposes of protein extraction from bacterial non-aqueous fraction, I made use of a 
relatively cost-effective, zwitterionic detergent called Empigen BB. It is a useful detergent 
that has been previously used in the solubilization of membrane proteins and biochemical 
analysis of keratins (Lowthert et al. , 1995). It has been shown to be very effective in 
membrane protein extraction, solubilizing larger amounts of proteins (Lowthert, Ku, 1995, 
Lukacova et al. , 1994, Vancraenenbroeck et al. , 2012). Even though it is a relatively 
harsher detergent than non-ionic detergents like βDDM, it has been shown to maintain 
proteins in their native conformations, as confirmed by antibody reactivity and other protein 
binding assays.  (Guo et al. , 2013, Wahl, 2002). Interestingly, viral antigens prepared with 
Empigen have been shown to illicit a greater antibody response than non-ionic detergents 
(Jennings and Erturk, 1990). The remarkable effectiveness of Empigen in the extraction 
of membrane proteins, even at concentrations twice its critical micelle concentration 
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(CMC) of 1.8 mM (Beckett and Woodward, 1963), could be because of the pattern of 
charge distribution in the zwitterionic molecule which, resembles membrane phospholipids 
such as phosphatidylcholine and thereby functions as an effective membrane mimic (Allen 
and Humphries, 1975). The membrane penetrative ability of Empigen could also be 
attributed to its small molecular size. Furthermore, given its relatively higher CMC, I would 
also expect to face minimal challenges in exchanging Empigen for other less harsh and/or 
compatible detergents for down-stream applications. Thus, based on its known 
performance and suitability, Empigen was the detergent of choice for extracting bacterial 
membrane proteins for our purposes.  
Purification of MBP-PPCS-Vpu 
The combination of a poly-histidine tag and Maltose binding protein (MBP) 
presents us with a great deal of flexibility and options regarding purification strategies of 
recombinant proteins (Nallamsetty and Waugh, 2007, Pryor and Leiting, 1997, Waugh, 
2005). As a first step towards the removal of cellular proteins and enrichment in the 
amount of MBP-Vpu, Empigen extracted non-aqueous fraction of BL21 cells harboring 
pTM975 was subjected to metal affinity purification (Figure V-1). The purification resulted 
in minimal loss of the MBP-PPCS-Vpu fusion in the flow-through and the wash steps. This 
could be due to the enhanced affinity of the N-terminal histidine tag on the MBP-PPCS-Vpu 
fusion with the cobalt ions due to a longer chain (10) of histidine residues. The challenging 
aspect of the recombinant protein expression through this strategy was that the yield of 
protein was significantly less than the yield from BL21- pTM875. I could speculate that the 
reason behind this could be the higher metabolic load imposed on the bacterial cells 
towards over-expressing a bulky fusion tag, especially in minimal media. Furthermore, the 
fusion was unstable upon storage at a range of cold temperatures and resulted in an array 
of degradation products. Since resolving such bands seemed challenging over a size 
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exclusion column, I proceed to 
perform a second round of 
purification exploiting the ability of 
Maltose binding protein to bind with 
amylose (di Guana et al. , 1988, 
Maina et al. , 1988, Riggs, 2001).  I 
observed that there was no 
significant affinity between the MBP 
part of the fusion and amylose 
(Figure V-2) and most of the proteins 
were found in the flow-through. 
Although this purification strategy 
has been relatively successful, there 
have been previous instances on the 
challenges encountered in this 
process by the lack of substantial 
binding between MBP and amylose 
(Lo-Man et al. , 1993, Rhyum et al. , 
1994). The binding of the MBP to 
amylose is strictly dependent on the 
correct biological activity and thus, 
proper folding of the MBP. Structural 
disturbances of the fusion partner, 
Vpu, in the present case, can also 
compromise the biologically active 
Figure V-1: Talon metal affinity chromatography 
purification of MBP-PPCS-Vpu. 
BL21 cells harboring pTM 975 were lysed after 
overnight expression and separated into aqueous 
and non-aqueous fractions, which, was treated with 
Empigen. Protein fractions were subjected to SDS-
PAGE followed by silver staining (A) and immuno-
blot analysis. (B). Detergent (Empigen)-soluble 
fraction containing MBP-PPCS-Vpu (Lane 1) was 
loaded onto a column containing Talon resin that 
was pre-equilibrated with 20 mM HEPES, pH 7.5, 
supplemented with 500 mM NaCl, 5 mM imidazole, 
and 1.5%% Empigen. Unbound proteins in the flow 
through were collected (Lane 2) and the column 
was washed consecutively with five different buffer 
solutions (20 mM HEPES, pH 7.5): W1 (Lane 3, 
buffer plus 500 mM NaCl), W2 (Lane 4, buffer plus 
500 mM NaCl and 1.5% Empigen), W3 (Lane 5, 
buffer plus 250 mM NaCl and 1.5% Empigen), W4 
(Lane 6, buffer plus 250 mM NaCl, 1.5% Empigen 
and 10 mM imidazole) and W5 (Lane 7, buffer plus 
250 mM NaCl, 1.5% Empigen and 15 mM 
imidazole). Most of the protein MBP-PPCS-Vpu (Lane 
8, indicated by arrows) was eluted with W5 buffer 
supplemented with 300 mM imidazole. 
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folding of MBP with respect to its 
amylose binding affinity (Park et al. , 
1998). Comparing the amylose 
purification of MBP-PPCS-Vpu 
complex in βDDM micelles (Figure 
II-17 in which, I did observe a small 
fraction of the fusion eluting by the 
addition of 10 mM maltose, I can 
also envision the effects of 
detergents in this process. MBP-PPCS-
Vpu in complex with a zwitterionic 
detergent, Empigen, appears to be 
in a biologically inactive form than 
some of the same protein in complex 
with a relatively mild, non-ionic detergent, βDDM. Since the binding affinities between 
MBP and amylose isn’t significantly affected by ionic strength of the buffer, the inability of 
MBP-PPCS-Vpu in Empigen micelles to bind to amylose can be attributed to the effect of the 
detergent on the structure/function relationship of the fusion protein rather than the 
possible unfavorable ionic interaction dynamics between amylose and the zwitterionic 
detergent. Owing to these challenges in purification and stability, I did not further pursue 
this strategy of obtaining Vpu for NMR characterization.  
Purification of PelB- Vpu 
Towards our effort to isolate His-tagged Vpu, expressed with the PelB leader 
sequence, the Empigen-solubilized fraction was subjected to metal affinity purification. In 
accordance with previous literature that was discussed above, I observed a net increase 
Figure V-2: Amylose resin purification of the MBP-
PPCS-Vpu complex. 
Protein fractions were subjected to SDS-PAGE 
followed by immuno-blot analysis, probed with anti- 
Vpu (A) and silver staining (B). Eluate from Figure 
V-1 was loaded onto an amylose resin pre-
equilibrated with 20 mM HEPES, pH 7.5, 
supplemented with 250 mM NaCl, 1.5% Empigen 
and 1 mM EDTA. Most of the protein remained 
unbound to the column, and was collected as flow-
through (Lane 2). There was no visible trace of the 
protein when the column was washed with 10 CV 
of the equilibration buffer (Lane 3) and when the 
column was subjected to 3 CV of the equilibration 
buffer supplemented with 10 mM maltose (Lane 4).  
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in the amount of total protein 
extracted from the non-aqueous 
fraction of the bacterial cells. This 
led us to incorporate stringent 
washes with imidazole for both the 
proteins, compared to the protocols 
that involved extraction with a less 
harsh, non-ionic detergent like 
βDDM. I observed that some higher 
molecular weight proteins co-
purified with PelB-Vpu. 
Contaminants around 25 kDa and 
higher were found to be in greater 
proportions than shown in (Figure 
V-3) in the absence of FeCl3, ZnSO4, 
CuSO4 and MnCl2. Cobalt and 
Nickel affinity purification are often 
contaminated with endogenous E. 
coli metal binding proteins like 
GlmS, SlyD, ArnA and Can 
(Andersen et al. , 2013, Robichon et 
al. , 2011).  The majority of these 
contaminants are stress-responsive 
proteins that are expressed in 
conditions such as heat shock, 
Figure V-3: Talon metal affinity chromatography of 
PelB-Vpu. 
BL21-pTM875 cells were lysed after overnight 
expression and separated into aqueous (Lane 1) 
and non-aqueous fractions, which, was treated with 
Empigen. Protein fractions were subjected to SDS-
PAGE followed by silver staining (A) and immuno-
blot analysis. (B). Detergent soluble fraction 
containing Vpu (Lane 2) was loaded onto a Talon 
column that was pre-equilibrated with 20 mM 
HEPES pH 7.5, 500 mM NaCl, 5 mM imidazole, 
and 1.5% Empigen. Unbound proteins in the flow 
through were collected (Lane 3) and the column 
was washed consecutively with five different buffer 
solutions (20 mM HEPES, pH 7.5): W1 (Lane 4, 
buffer plus 500 mM NaCl), W2 (Lane 5, buffer plus 
500 mM NaCl and 1.5% Empigen), W3 (Lane 6, 
buffer plus 250 mM NaCl and 1.5% Empigen), W4 
(Lane 7, buffer plus 250 mM NaCl, 1.5% Empigen 
and 5 mM imidazole) and W5 (Lane 8, buffer plus 
250 mM NaCl, 1.5% Empigen and 10 mM 
imidazole). Most of the protein Vpu (Lane 9) was 
eluted with W5 buffer supplemented with 300 mM 
imidazole. 
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nutrient starvation and oxidative 
damage (Bolanos-Garcia and 
Davies, 2006). Supplementing the 
minimal media with various trace 
metals indeed helped decrease the 
expression levels of these 
contaminants to enrich our protein of 
interest. I did observe some fraction 
of PelB-Vpu eluting in the lower 
imidazole washes. This could be 
because of changed interaction 
dynamics between cobalt ions and 
the protein surrounded by 
zwitterionic detergent micelles. To 
remove the co-purified contaminants, the eluate was concentrated and the proteins were 
resolved by size exclusion chromatography. PelB-Vpu eluted as a single major peak, 
which was easily fractionated (Figure V-4). The size of the protein detergent complex in 
this case, approximately 60 kDa, roughly indicates a possibility of a dimeric 
oligomerization arrangement of PelB-Vpu in Empigen micelles.  
Detergent exchange 
After I purified PelB-Vpu in complex with Empigen to substantial levels of purity by 
using metal affinity purification and size exclusion chromatography, I proceeded towards 
replacing Empigen for more NMR compatible detergents. A major obstacle to membrane 
protein structure determination is the selection of a detergent micelle that mimics the 
native lipid bilayer. Since the effects of protein-detergent interactions on the structure of 
Figure V-4: Size-exclusion chromatography of 
concentrated metal-affinity purified PelB-Vpu.  
Eluate from Figure V-3 was subjected to SEC-
FPLC. Sec resin: Superdex 200 10/300 GL; Flow-
rate: 0.5 mL/min, Running buffer: 20 mM HEPES, 
pH 7.5, 250 mM NaCl, 5% glycerol and 1.5% 
Empigen. The major peak at 14.58 mL contained 
Vpu. The column was calibrated with cytochrome c 
(A), carbonic anhydrase (B), albumin (C), alcohol 
dehydrogenase (D), β-amylase (E) and blue 
dextran (F) and a standard curve was obtained as 
shown in the inset. The size of the Vpu- Empigen 
complex was estimated to be 60 kDa. 
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membrane proteins are hard to 
predict, detergents are selected by 
exhaustive screening. NMR 
structures of a large number of 
single- helix membrane protein have 
been solved in DPC micelles 
(Damberg et al. , 2001). Lysolipids, 
which are derivatives of E. coli lipids 
dipalmitoyl 
glyceorolphosphoglycerol and 
dipalmitoyl glycerolphosphocholine, 
like 1-Palmitol-2-Hydroxy-sn-Glycero-3-Phospho-(1'-rac-Glycerol) -Sodium Salt 
(LPPG)and 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphocholine (LPPC) respectively, 
have also been shown to be very favorable towards elucidating membrane protein 
structures (Krueger-Koplin et al. , 2004). The short chain lipid, 1,2-Dihexanoyl-sn-Glycero-
3-Phosphocholine (DHPC), was used to solve the structure of the M2 proton channel of 
the influenza A virus (Schnell and Chou, 2008) and most importantly, the full length 
structure of Vpu (Zhang, Lin, 2015) while LysoFos Glycerol 14 or 1-Myristoyl-2-Hydroxy-
sn-Glycero-3-Phospho-(1'-rac-Glycerol) -Sodium Salt) (LMPG) was instrumental in 
characterizing the solution structure of influenza B virus proton channel (Wang et al. , 
2009). I exchanged Empigen with the above mentioned detergents by first, binding the 
Empigen solubilized PelB-Vpu first to a metal affinity resin and then gradually replace 
Empigen with the new detergent by applying wash and elution buffers in multiple batches. 
The elutions, when analyzed with SDS-PAGE followed by silver staining and immunoblot 
analysis, reveal that depending on the initial detergent before the addition of the SDS 
Figure V-5: Talon metal affinity chromatography 
purification and detergent exchange. 
The major peak from Figure V-4 containing purified 
Vpu- Empigen complex was subjected to another 
round of talon purification to exchange Empigen to 
LPPC, DHPC, LPPG and LMPG detergents. The 
elutions of each of the purification were analyzed 
by SDS PAGE followed by silver staining (A) and 
immuno-blotting (B). Arrows indicate the different 
oligomeric states of PelB-Vpu. 
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loading buffer, the protein migrated 
as a monomer and/or an oligomer 
(Figure V-5). I was unable to elute 
any detectable amounts of PelB-Vpu 
with LPPC.  In case of DHPC, the 
protein that was illuminated by 
immunoblot analysis with antibodies 
against Vpu was roughly around 25 
kDa. I hypothesize that the larger 
size could be due to the protein 
migrating in an oligomeric state.  The 
same band is also visualized with 
LPPG, along with another protein 
band at approximately 17 kDa, the 
usual size marker PelB-Vpu aligns 
with. Higher molecular weight bands 
were not observed in LMPG 
samples and the protein aligned with 
the usual size of PelB-Vpu. Proteins 
migrating in their oligomeric states in 
a denaturing gel, in spite of the lack 
of in vitro crosslinking, especially in 
case of DHPC, has also been 
observed in case of Thermotoga 
Figure V-6: Extraction of Vpu with Empigen and 
metal affinity purification and detergent exchange 
into DPC micelles.   
Non- aqueous fraction of BL21-pTM 875 cells was 
harvested after overnight protein expression and 
was treated with Empigen. Protein fractions were 
subjected to SDS-PAGE followed by silver staining 
(A) and immuno-blot analysis. (B). Empigen 
soluble fraction containing Vpu (Lane 1) was 
loaded onto a Talon column that was pre-
equilibrated with 20 mM HEPES pH 7.5, 500 mM 
NaCl, 5 mM imidazole, and 1.5% Empigen. 
Unbound proteins in the flow through were 
collected (Lane 2) and the column was washed 
consecutively with four different buffer solutions (20 
mM HEPES, pH 7.5): W1 (Lane 3, buffer plus 500 
mM NaCl), W2 (Lane 4, buffer plus 500 mM NaCl 
and 0.2% DPC), W3 (Lane 5, buffer plus 250 mM 
NaCl and 0.1% DPC), and W4 (Lane 6, buffer plus 
250 mM NaCl, 0.1% DPC and 10 mM imidazole). 
Most of the protein Vpu (Lane 7) was eluted with 
W4 buffer supplemented with 300 mM imidazole. 
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maritima membrane protein TM1514 (Columbus et al. , 2006).  
To obtain PelB-Vpu in DPC 
micelles, protein extracted from the 
non-aqueous fraction of BL21- pTM 
875 by Empigen was purified and 
underwent detergent exchange in a 
single metal affinity purification step 
(Figure V-6). The protein was 
relatively pure than the first round of 
metal affinity purification when the 
protein was eluted complexed with 
Empigen micelles (Figure V-3). I 
proceeded to concentrate the 
fraction eluted with high imidazole and further purify PelB-Vpu in DPC micelles from 
unwanted contaminants by size exclusion chromatography (Figure V-7). The major peak, 
which contained PelB-Vpu, was fractionated stringently so as to totally eliminate the 
possibility of contamination with proteins eluting later and closely following the major peak.  
Solution NMR of PelB-Vpu in different detergents 
Having obtained Pel-Vpu in complex with different detergent micelles, I proceeded 
towards characterizing the protein- detergent complexes by biomolecular solution NMR 
spectroscopy. Suitability for structural studies can be judged by spectral quality. I 
employed Transverse relaxation optimized spectroscopy – heteronuclear single quantum 
coherence (15N-TROSY-HSQC) experiments towards this purpose. This technique is a 
common measure of protein folding and monitoring backbone glycine (Gly) amide and 
tryptophan (Trp) side-chain resonances, with their characteristic chemical shifts allowing 
Figure V-7: Size-exclusion chromatography of 
concentrated metal-affinity chromatography -
purified Vpu. 
Eluate from Figure V-6 was subjected to SEC-
FPLC. Sec resin: Superdex 200 10/300 GL; Flow-
rate: 0.5 mL/min, Running buffer: 20 mM HEPES, 
pH 7.5, 250 mM NaCl, 5% glycerol and 0.1% Fos-
choline-12. The major peak at 12.8 mL contained 
Vpu. 
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me to accurately judge the conformational stability of the protein. I observe that the spectra 
of PelB-Vpu in most detergent micelles, except in DPC, over-estimates the total number 
of resonances that are to be expected (112). Specifically, I observe more than the 
expected two Trp resonances for the PelB-Vpu in complex with LPPG and DHPC micelles. 
Interestingly, in case of PelB-Vpu in DHPC micelles, I observe nearly two fold of expectant 
resonances. Furthermore, these resonances tend to decrease in number with increase in 
data acquisition time. The addition of 50 mM NaCl to the NMR sample did not significantly 
improve the spectra. I suspect that this heterogeneity of the spectra could be a result of 
protein aggregates or the presence of different oligomers at the sample conditions the 
spectra was obtained at. The presence of such oligomers was described in the previous 
Figure V-8: 15N-1H HSQC spectra of Vpu in complex with various detergents. 
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section (Figure V-5) for DHPC and LPPG. Another cause of this heterogeneity of spectra 
could be that fact that some micelles may have only one protein molecule per micelle while 
other micelles may have a different number of a protein to micelle ratio. In a study by 
McDonnell and Opella (1993), problem of similar kind was solved under conditions where 
the micelle concentration was much higher than the apparent protein concentration. But, 
in our case, increasing the concentration of DHPC above 50 mM resulted in most of the 
protein coming out of the solution as a precipitate. The number of Trp resonances obtained 
in case of PelB-Vpu in complex with LMPG and DPC micelles is in accordance to our 
expectations. Comparison of the shape of the two spectra in each detergent implies that 
each Trp could be in a different physiological environment. Indeed, in case of PelB-Vpu, 
one of the Trp is localized in the transmembrane domain and the other in the soluble 
cytoplasmic domain. But, in case of both these detergent –protein complexes, the overall 
spectral quality was poor and would be extremely challenging to resolve. In case of PelB-
Vpu in DPC micelles, the under-estimation of detectable resonances could be because of 
slow tumbling rates of the protein-detergent complex. The size of the PelB-Vpu – DPC 
complex can be estimated to be approximately 150 kDa from the major peak of the size 
exclusion chromatogram (Figure V-7). Such a size could result in lower dynamics resulting 
in a few undetectable resonances.  
Role of the PelB signal peptide. 
Despite the seemingly uniform preparation (as judged by DLS and SEC-HPLC), 
the NMR results clearly point to conformational heterogeneity that reveals itself at the 
molecular level. I hypothesized that one of the factors that was responsible for the 
heterogeneity of the NMR spectra discussed above was the possible co-existence of 
multifarious conformations of the protein-detergent complexes. Specifically, I suspected 
that this conformational complexity may be ascribed to the hydrophobic PelB signal 
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peptide that was left uncleaved. The 
presence of two hydrophobic helical 
domains in tandem could complicate 
the manner in which detergent 
micelles interact with the protein. So, 
I proceeded to undertake efforts to 
remove PelB signal peptide from 
Vpu in vitro by digesting the protein 
with cyanogen bromide. Cyanogen 
bromide cleaves a peptide at 
methionine residues (Gross, 1967, 
Gross and Witkop, 1961, Villa et al. , 
1989). A complete digestion of the 
PelB-Vpu protein would generate a 
largest fragment consisting of the N-
terminal domain, transmembrane 
domain and the first C-terminal 
helical domain of Vpu.  I observe that 
the reaction did not achieve 
completion even after prolonged 
incubation and our efforts to 
separate each fragment by metal 
affinity purification resulted into 
multiple fragments in each fraction 
(Figure V-9). The challenging aspect of separating these fragments was further illustrated 
Figure V-9: Cyanogen bromide digestion of PelB-
Vpu. 
Purified Vpu from Figure V-4 (lane 2) was subjected 
to cyanogen bromide cleavage. After incubation, 
the reaction (lane 3) was loaded onto a Talon resin 
that was pre-equilibrated with 20 mM HEPES, pH 
7.5, supplemented with 250 mM NaCl and 1.5% 
empigen. Unbound proteins in the flow through 
were collected (lane 4). The column was washed 
with 5 CV of the equilibration buffer (lane 5) and 
bound proteins were eluted with the same buffer 
supplemented with 300 mM imidazole (lane 6). The 
protein fractions were subjected to SDS-PAGE 
followed by silver staining (A) and immuno-blot 
analysis, probed with anti-Vpu. (B). Black arrows 
depict the potential cleavage sites on the PelB-Vpu 
sequence (C). 
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by performing a size exclusion 
chromatography where I observe 
that most of the peaks within the first 
column volume of the SEC column 
(24 mL), within which Vpu is 
expected to elute, were poorly 
resolved (Figure V-10). The 
challenges with this procedure were 
further compounded by the fact that 
the harsh nature of the reaction 
conditions led to the precipitation of 
the protein, which seriously hampers the possibility of obtaining sufficient amount of 
protein for structural studies.   
Conclusions 
I conclude that it is necessary to revisit our strategies of obtaining recombinant 
Vpu. It is demonstrated from the NMR spectroscopy studies that the presence of additional 
hydrophobic tags, such as an uncleaved signal peptide, greatly impairs the possibility of 
obtaining well-resolved signals. This could be due to sample heterogeneity. The presence 
of an additional hydrophobic segment closely preceding the hydrophobic transmembrane 
domain of Vpu could potentially complicate the manner of interactions of PelB-Vpu with 
the various membrane-mimetic environments used, compared to a situation where the 
PelB signal peptide was cleaved in vivo in the bacterial cells and the protein was obtained 
in a relatively native state. It could also be possible that the PelB segment and the 
transmembrane domain of Vpu could interact with each other, potentially masking 
surfaces on the transmembrane domain which otherwise interact with the lipid. Since the 
Figure V-10: Size-exclusion chromatography of 
cyanogen bromide digested products. 
The sample from Figure V-9, Lane 3 was subjected 
to SEC-FPLC. Sec resin: Superdex 200 10/300 GL; 
Flow-rate: 0.5 mL/min, Running buffer: 20 mM 
HEPES, pH 7.5, 250 mM NaCl and 1.5% Empigen. 
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dynamics of the soluble C-terminal domain of Vpu have been found to be dependent on 
the transmembrane domain (Zhang et al. , 2015), it can be clearly envisioned that that the 
unwanted hydrophobic interactions mentioned above can have far reaching 
consequences on the whole protein. When there is an existence of such dynamic, 
interconverting conformations, each conformation results in spin states with different 
intrinsic resonance frequency. Depending on the comparative rate of exchange between 
these different states and the difference in resonance frequencies, peaks corresponding 
to each conformation could be observed, thereby over-estimating the number of 
theoretical expected peaks (Sanders et al. 2006).  
Key questions about attributes of Vpu such as, its oligomeric state, combined with 
the fact that Vpu interacts with a range of host factors that are critical towards 
understanding the structure-function relationship in this protein remain unanswered. 
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VI. Summary and outlook 
HIV-1 Viral protein U (Vpu) is a type III membrane protein which is expressed in 
infected host cells. It is involved in efficient viral release and propagation from the host 
cells. The protein achieves it by binding to host cell viral restriction factors like CD4 and 
BST-2 and in most cases, tagging them for lysosomal and/or proteasomal degradation. 
As detailed in Chapter I, binding is achieved by the involvement of both the trans-
membrane and the cytoplasmic domain and key structural components in these domains 
are implicated to be critical for these functions. Unravelling this structural-function 
relationship of Vpu was the primary motivation behind this study to elucidate a structural 
model of the protein by X-ray crystallography.  
During the course of this research, there were significant challenges towards my 
goal. Obtaining protein samples which are amenable for setting up crystallization trials 
proved challenging, especially when Vpu was expressed in fusion with a soluble bacterial 
protein like Mistic and the maltose binding protein (MBP). Although there are fewer cases 
of successful vs unsuccessful heterologous expression and enriched isolation of 
eukaryotic membrane proteins in bacteria for structural studies, the choice of the bacterial 
expression system, in case of Vpu, was dictated by the fact that the protein lacked typical 
eukaryotic post translational modifications, such as glycosylation. In the natural host, 
targeting and retention of this protein to the membranes is driven by amino acid motifs in 
the trans-membrane and cytoplasmic domain itself (Pacyniak et al. , 2005, Ruiz et al. , 
2008, Vigan and Neil, 2011). Since such an arrangement was shown to be non-adaptive 
in a vastly different prokaryotic expression system, I relied on known bacterial targeting 
elements to target and integrate Vpu in the bacterial inner membranes.  
Expression of Vpu with Mistic did result in fair amounts of recombinant proteins. 
Mistic is an unusual membrane associating protein that has been shown to tightly 
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associate with membranes in vivo and membrane-mimetic environments in vitro, even if it 
lacks characteristic membrane interaction segments. The post-translational self-
association of Mistic in biological membranes and its interactions in vitro with ionic and 
zwitterionic detergents is brought about by polar rather than hydrophobic interactions 
(Broecker et al. , 2014). Subsequently it was used to express functional versions of 
typically difficult to express proteins like the G protein coupled receptors (GPCRs) in E. 
coli (Chowdhury et al. , 2012, Petrovskaya et al. , 2010). Contrary to expectations, the 
Mistic-Vpu fusion protein was very unstable and prone to degradation and aggregation 
over time. Furthermore, the fusion was cleavable only under extreme conditions which not 
only resulted in an unfavorable environment for the stability of the proteins but also yielded 
very less quantities of cleaved Vpu. 
Even more than Mistic, the E. coli maltose binding protein (MBP) has been 
extensively used in facilitating the production of recombinant proteins in bacterial systems 
as detailed in Chapter III. I experimented with different construct designs with regards to 
linkers and site-specific proteases. MBP-Vpu fusion containing a Tobacco etch Virus 
(TEV) protease site (MBP-TEV-Vpu) was found to fractionate equally between the water 
soluble and insoluble fractions of the bacterial cell. Although this protein was very 
conducive to extraction from the membranes by a wide range of detergents, metal affinity 
purified MBP-TEV-Vpu was completely resistant to cleavage with TEV protease. Due to the 
use of Gateway recombination sequences for the creation of the expression vector, the 
linker between MBP and Vpu translated to a long stretch of amino acids which were 
predicted to render the whole fusion too flexible to crystallize. Hence, I resorted to the 
usage of a shorter linker which also served as a site for cleavage with PreScission 
protease (MBP-PPCS-Vpu). This fusion was seen to be efficiently targeted to the membranes 
with the help of the PelB leader peptide. But, the fusion remained resistant to cleavage by 
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PreScission protease when attempted under preparative conditions. Progress towards the 
further use of the uncleaved fusion was hampered by the fact that MBP-PPCS-Vpu co-eluted 
with a similar-sized impurity by metal affinity chromatography. Moreover, Vpu and the 
contaminant could not be efficiently resolved by size exclusion chromatography. Next, I 
attempted a different strategy based on affinity chromatography using immobilized-
amylose resin relying on the ability of MBP to bind to short alpha-glucose polymers. This 
also proved to yield unsatisfactory results. In addition, the amylose affinity 
chromatography also indicated the fact that MBP-PPCS-Vpu was present in solution as a 
mixture of well-folded and mal-folded forms judging by its affinity to amylose. This in turn 
could point towards the protein being present in different conformations in solution which 
would be a major hindrance towards crystallization. 
My efforts to express Vpu as a type I membrane protein in E. coli with the help of 
the PelB signal peptide proved successful. Extensive characterization revealed that the 
protein was efficiently targeted to the inner membranes of the bacteria. In addition, 
towards the membrane topology of this protein, I showed that the C-terminal domain of 
Vpu was protected by the bacterial inner membranes. I was able to extract the protein 
using mild detergents such as bDDM and isolate the protein from other cellular impurities 
in an extremely pure form using metal affinity chromatography and size exclusion 
chromatography. Although mass spectrometry revealed the failure of periplasmic 
peptidases to remove PelB from Vpu, the protein was tested to be in a functional 
conformation when it bound selectively to the transmembrane and cytoplasmic domain of 
heterologously expressed human CD4. The presence of expected secondary structure 
elements was shown alternatively using circular dichroism, which also revealed the 
stability of the protein in conditions of varying ionic strengths and up to a temperature of 
approximately 40 ºC. Lastly, its excellent theoretical suitability for crystallization was also 
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demonstrated by the presence of a mono-disperse PelB-Vpu-bDDM complex at 
concentrations of 10 mg/mL.  
Despite the promising biochemical and biophysical characteristics of the purified 
Vpu preparations, crystallization of the PelB-Vpu-bDDM complex was largely 
unsuccessful so far. When subjected to extensive screening with various salts, buffers, 
precipitants, ionic strength among others, immediate precipitation was observed for most 
of the conditions. In order to crystallize PelB-Vpu in an environment more native to protein, 
I employed the technique of Lipid cubic phase (LCP) crystallization. Some conditions 
showed promise towards this technique when I was able to detect appreciable rates of 
labeled PelB-Vpu diffusion in the LCP using fluorescence detection after photo-bleaching 
(FRAP). But, in spite of this, I hitherto could not identify any conditions that supported the 
crystallization of the protein and would lead to further optimization of conditions. 
In parallel to our thus-far unsuccessful crystallization efforts, I turned to another 
method for structure determination, namely NMR spectroscopy. Bacterial cells harboring 
plasmids for the expression of PelB-Vpu were successfully adapted to protein expression 
in M9 minimal medium. Upon successful purification, the protein was obtained in complex 
with various detergents and lipid. Solution NMR spectroscopy experiments like 15N- 1H 
HSQC revealed heterogeneous spectra of PelB-Vpu in complex with various membrane-
mimetic environments. Non-reproducibility of well-defined, expectant number of 
resonances when compared to a recently published full length solution NMR structure of 
Vpu in DHPC micelles (Zhang et al. , 2015) strongly indicated the possible role of the 
hydrophobic PelB sequence towards the discrepancies observed in the NMR spectra. 
Specifically, the presence of a second hydrophobic segment with the hydrophobic 
transmembrane domain of Vpu could result in heterogeneous interaction of PelB-Vpu with 
membrane mimetic environments.   
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The Vpu cytoplasmic domain and the transmembrane domain have been 
previously studied by solution and solid state nuclear magnetic resonance spectroscopy 
(NMR) resulting in independent structures of the either domain (Sharpe et al. , 2006, 
Wittlich et al. , 2009). A full-length NMR structure of the protein was recently published 
(Zhang, Lin, 2015). From these studies, it was observed that the relative mobility of the 
cytoplasmic helices was dependent on the membrane mimetic environments used. In 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) proteoliposomes, the helices were 
flexible and could be either arranged in a linear or in a U -shaped orientation as against in 
1,2-Dihexanoyl-sn-Glycero-3-Phosphocholine (DHPC) micelles, where the backbone 
dynamics were more restricted and the cytoplasmic helices adopted well-defined U-
shaped loop region between them. It was also shown in the full-length structure that the 
transmembrane domain influences the conformation, structure and dynamics of the C-
terminal domain and vice versa. 
Judging by the above mentioned dependence of the protein on the membrane- 
mimetic environment, I predict that the way forward in future structural studies in Vpu is to 
over-express the protein in a more native environment, such as mammalian cells. Insect 
cell expression systems can also be considered (Sarramegna et al. , 2003). Cell free 
systems, especially the eukaryotic wheat germ extracts (Anderson et al. , 1983, Madin et 
al. , 2000, Sawasaki and Endo, 2004), could also be used for protein synthesis. Addition 
of suitable lipids in solution can create a favorable environment for the membrane protein 
to be synthesized directly into a defined membrane-mimetic environment of choice that 
would allow solubility and functional folding of the proteins (Elbaz et al. , 2004, Ishihara et 
al. , 2005, Klammt et al. , 2004, Klammt et al. , 2005). Xenopus laevis oocytes can also 
be used for expression (Buckingham et al. , 2006). This system has been used widely for 
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the expression of receptors and ion-channels, including Vpu, to demonstrate its ion 
channel activity (Coady et al. , 1998) 
A major challenge towards structural studies of hydrophobic membrane proteins 
using X-ray crystallography is the growth of well-ordered 3D crystals of membrane 
proteins. Especially, proteins with small extra-membrane domains, such are Vpu could be 
difficult to crystallize because they have reduced surface area for type II crystal contacts 
and the presence of detergent micelles could have a restrictive effect as well. One of the 
ways to facilitate the process could be to generate monoclonal antibodies against Vpu and 
co-crystallize the protein with these structural monoclonal antibody fragments (Hunte and 
Michel, 2002).  
For the purposes of crystallization, lipid cubic phase could play an important role 
because of its flexibility to allow the incorporation of various kinds of lipids thus providing 
a stabilizing environment in which the protein is initially embedded and then crystallization 
is driven by lateral diffusion of the protein in LCP upon the addition of precipitants (Nollert 
et al. , 2002). Due to the relatively slow diffusion rates of membrane proteins in LCP, 
crystals obtained by this method are usually found to be smaller than the ones obtained 
from in surfo methods (Liu et al. , 2014b). Small crystals could be challenging to detect 
and harvest and are more susceptible to X-ray radiation damage, thereby hampering the 
collection of high-resolution diffraction data from these crystals. The technique of Serial 
femtosecond crystallography was developed to obtain time-resolved diffraction patterns 
from small crystals with minimal radiation damage (Chapman et al. , 2011, Kupitz et al. , 
2014). This technique has been adapted to use with LCP crystallization (Liu et al. , 2014a, 
Liu et al. , 2013, Liu, Wacker, 2014b, Weierstall et al. , 2014) thereby greatly benefitting 
the prospects of this technique.  
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The HIV-1 Vpu has been an active subject of research in the scientific community. 
The various important roles played by the protein towards efficient viral release from 
infected host cells makes it an attractive anti-viral drug target. The above mentioned 
options will be explored in the future in the hope of elucidating a reliable structural model 
of not only Vpu, but also its manner of interactions with its binding partners. This could 
help in the formulation of a successful strategy to halt the spread of the devastating 
epidemic caused by HIV-1. 
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